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ABSTRACT 
Synthesis, Characterization, and Biological uses of          
Carbon Nanoparticles  
by 
Daniela C. Marcano 
This dissertation demonstrates the radical scavenging properties of poly(ethylene 
glycol)-functionalized hydrophilic carbon clusters (PEG-HCCs, ~50 nm size) in vitro and 
in vivo. Also, it describes the new synthesis of improved graphene oxide (IGO, 5-10 µm).  
Many diseases have been associated with oxidative stress (OS) which is caused 
when the production of reactive oxygen species (ROS), such as superoxide (O2•-) and 
hydroxyl radical (•OH), overcome the scavenging efficiency of living organisms. It is 
known that ROS production is worsened during traumas related to ischemic events and 
subsequent reperfusion in which the treatment with fast and effective antioxidants is 
critical to prevent cell and tissue damage.  PEG-HCCs are carbon nanoparticles that 
showed O2•- and •OH scavenging properties according to electron paramagnetic 
resonance (EPR) experiments and peroxyl scavenging properties based on oxygen radical 
absorbance capacity (ORAC) assays. The O2•- quenching capability was also examined in 
vivo using a mild traumatic brain injury (mTBI) model complicated with hypotension. As 
result of the PEG-HCCs treatment, the cerebral blood flow (CBF) was restored while 
normalizing O2•- and nitric oxide (NO•) levels, primarily in the cerebral vasculature.  
 
 
 Presently, Hummers’ method (KMnO4, NaNO3, H2SO4) is the most common 
procedure used for preparing graphene oxide. The improved method developed and 
described in this dissertation is based on the exclusion of NaNO3, an increased amount of 
KMnO4, and the addition of H3PO4 (9:1 mixture of H2SO4:H3PO4), providing a greater 
amount of hydrophilic oxidized graphene material as compared to Hummers’ method.  
Even though the GO produced by this new method is more oxidized than that prepared by 
Hummers’ method, when both are reduced in the same chamber with hydrazine, 
chemically converted graphene (CCG) produced from this new method is equivalent in 
its electrical conductivity.  In contrast to Hummers’ method, the new procedure does not 
generate toxic gas and the temperature is easily controlled. This improved synthesis of 
GO may be important for large-scale production of GO as well as the construction of 
devices composed of the subsequent CCG. 
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Chapter 1 
                    Antioxidant efficacy of 
PEGylated Carbon Particles 
1.1. Introduction 
It has been reported that approximately 5% of inhaled oxygen is metabolized by 
cells and converted to reactive oxygen species (ROS) such as superoxide (O2•-), hydrogen 
peroxide (H2O2) and organic peroxides, and hydroxyl radical (•OH).1,2 These ROS are 
necessary for the signaling pathways in biological processes3,4 such as cell migration, 
circadian rhythm, stem cell proliferation, and neurogenesis.5 In healthy systems, the ROS 
are efficiently removed by the defensive enzymes superoxide dismutase (SOD), catalase, 
and antioxidants like glutathione, vitamin A, ascorbic acid,  uric acid, hydroquinones, and 
vitamin E.6 When the production of ROS overwhelms the scavenging ability of the 
defense system, oxidative stress occurs, causing dysfunctions in cell metabolism. 
Additionally, the ROS-induced oxidation of macromolecules such as lipoproteins, DNA 
2 
 
and RNA, compromises cellular integrity.7,8 It is still uncertain whether the uncontrolled 
generation of ROS is the cause or a consequence of several diseases9 but the oxidative 
stress that they cause has been associated with cardiovascular dysfunction,10,11 cancer,12,13 
rheumatoid arthritis,14,15 inflammatory response,16 diabetes,17 aging,18 and 
neurodegenerative19 conditions including Alzheimer’s disease20,21 and Parkinson’s 
disease.21 The overproduction of ROS is also observed in injuries caused by ischemia and 
blood reperfusion, heat, trauma, freezing, severe exercise, toxins, radiation and infection 
pathologies.2 
In cells, O2•- is generated by different oxidases including xanthine oxidase (XO) 
and NADPH oxidases.  H2O2, which is produced by oxidases or by the SOD-assisted 
dismutation of O2•-, is a long lived, membrane permeable molecule, able to migrate away 
from the site of production.2 The problem begins when H2O2 interacts with transition 
metals such as copper and/or iron released from metalloproteins during ischemic 
pathologies, to produce •OH (the Fenton reaction).22 In addition to ROS, reactive nitrogen 
species (RNS) such as nitric oxide (NO•), nitrogen dioxide, and dinitrogen trioxide are 
present in all organisms. NO•  is an important molecule produced by nitric oxide synthase 
(NOS) enzymes.23 It is involved in neurotransmission, blood pressure regulation, smooth 
muscle relaxation and immune regulation processes. During an inflammatory event, the 
production of O2•- and NO•  is triggered, and under these conditions, both radicals may 
react to produce peroxynitrite (ONOO-), a very potent oxidizing molecule which causes 
protein nitration and DNA fragmentation.9 
3 
 
One way to treat these detrimental pathologies is by supplying antioxidant 
molecules or particles that rebalance the disturbed oxidative condition.3 We recently 
developed a biocompatible carbon particle, the PEGylated hydrophilic carbon cluster 
(PEG-HCC)24 that has shown the ability to scavenge oxyradicals25 due to its graphitic 
domains. These PEG-HCCs are about 50 nm in size and are 85% PEG by weight.24,26 It 
has been reported that PEG chains can interact with •OH primarily through H abstraction 
(k = 2.4 x108 M-1s-1).27 PEG chains also have the ability to sequester transition metal ions 
which are responsible for the Fenton reaction. Hence, there is a question whether the 
antioxidant activity of the PEG-HCCs is primarily due to the PEG addends where they 
act as pre-antioxidants by trapping metal ions and/or they interact with •OH. In this work, 
we evaluated the •OH, O2•-, NO•, and ONOO- scavenging properties of PEG-HCCs using 
electron paramagnetic spectroscopy (EPR), oxy-hemoglobin, cytochrome c, and 
pyrogallol red decomposition assays to elucidate the mechanisms by which PEG-HCCs 
might inhibit ROS.  
 
1.2. Experimental Procedures 
5-(Dietoxyphosphoryl)-5-methylpyrrole-N-oxide (DEPMPO) was obtained from 
Santa Cruz Labs (cat # sc-202132).  Ferrous sulfate heptahydrate (FeSO4·7 H2O, cat # 
M1-03965-0500), cupric sulfate pentahydrate (CuSO4·5H2O, cat # C493-500), nitric acid 
(HNO3, cat #A200-212), H2O2 (30% in water, cat # MHX06351), potassium phosphate 
monobasic (KH2PO4, cat # P284-500), potassium permanganate (KMnO4, cat # P279-
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500), ethanol (EtOH, cat # 04-355-222), sulfuric acid (H2SO4, cat # A300-212), and 
sodium hydroxide (NaOH, cat # S318) were purchased from Fisher Scientific. Potassium 
phosphate dibasic (K2HPO4, cat # 3252-01) was purchased from J. T Baker. 
Methoxypolyethylene glycol amine (PEG, cat # 06679, MW 5000), Chelex (Cat # 
C7901), ethylenediaminetetraacetic acid tetrasodium salt hydrate (EDTA, cat # E5391), 
catalase from bovine liver (cat # C40), triethanolamine (TEA, cat # 90279), 
methylsulfoxide (DMSO, cat # W387509), sodium perchlorate (NaClO4, cat # 410241), 
horseradish peroxidase (HRP, cat # P8375), deferoxamine mesylate (DFO, cat # D9533), 
2,2’-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt (ABTS, cat # 
A9941), pyrogallol (cat # P0381), sodium nitrite (NaNO2, cat # 237213), ascorbic acid 
(acid form, cat # A7506), caffeic acid (cat # C0625), (±)-6-hydroxy-2,5,7,8-
tetramethylchromane-2-carboxylic acid (trolox, cat # 238813), hypoxanthine (HX, cat # 
H9636), cytochrome c from equine heart (cat # C4186), xanthine oxidase (XO, cat # 
X4875), and superoxide dismutase (SOD, cat # S9697)  were purchased from Sigma-
Aldrich. Potassium superoxide (KO2, cat # 355420250) was obtained from Acros 
Organics. The inductively couple plasma (ICP) standard for iron (cat # ICP-AM-6)   and 
the dialysis membrane (MWCO 1000 and MWCO 5000) were purchased from High-
purity standards and Biotech respectively. 
PEG-HCCs were prepared, purified, and characterized as reported previously.24 
Briefly, HCCs were prepared from single-walled carbon nanotubes (SWCNTs), which 
are 1 nm wide and have a high solubility in oleum (400 ppm), by an oxidative procedure 
in which oleum and nitric acid mixture was employed. The SWCNTs (250 mg) were 
dissolved in oleum (125 mL) in a three-neck, 1 L round-bottomed flask with all joints 
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sealed with Teflon and stirred for 5 days to disentangle them. The solution was then 
cooled to 0 °C with an ice bath, and an ice cold 1:1 mixture of oleum and nitric acid (62.5 
mL/62.5 mL) was added in 20 mL portions. During the addition of this mixture, the 
temperature of the solution was monitored to ensure that it never exceeded 60°C. When 
60 °C was reached, the mixture was allowed to cool until the temperature returned to 10 
°C before adding the next portion. The addition process took approximately 1 h. The final 
proportion of oleum/nitric acid was 3:1. When the addition of the acidic mixture was 
completed, the ice bath was removed and the solution was heated to 65 °C and stirred for 
90 min. The solution was then cooled to room temperature and carefully poured onto ice 
(400 mL) to quench the reaction. The resulting solution was filtered through a PTFE 
membrane (0.45 µm pore size). The pH of the liquid coming through the filter is checked 
until it reaches pH 6. At this point, the addition of water is terminated and all of the liquid 
is removed by filtration, but the solid still remains moist. Methanol (150 mL) is slowly 
added to dissolve the solid, then ether (500 mL) is added to precipitate the solid and the 
liquid is removed by filtration. The final evaporation of the ether was done by placing the 
moist HCCs in a 50 mL beaker and using a hot plate, slowly allowing the HCCs to heat 
while continually pulverizing them with a Teflon spatula resulting in a fine, dry powder 
that was dried in a vacuum desiccator for 12 h to yield 112 mg of HCCs. PEG-HCCs 
were prepared by coupling 5,000 MW methoxy(polyethylene glycol) amine (PEG) to the 
carboxylic acids on the HCCs. In general, HCCs (25 mg, 2.08 mmol of carbon) were 
added to DMF (25 mL), and the mixture was bath sonicated for 30 min until all of the 
HCCs were dissolved. DCC (172 mg, 0.835 mmol), DMAP (2 flakes), and  PEG (208 
mg, 0.042 mmol) were added and stirred for 24 h. The solution was purified by dialysis 
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in DMF and then water (50,000 MW cutoff dialysis bag, Membrane Filtration Products, 
Inc.), followed by passage through a PD-10 column(GE Healthcare) and rotavap to 
furnish 40 mL of PEG-HCCs with a carbon core concentration of  0.500 mg/mL (Figure 
A1, Appendix A). The nanoparticle concentration was estimated based on the carbon core 
absorbance at 763 nm using an extinction coefficient of 0.01040 L/mg. This wavelength 
was not used for biological assays. Thermogravimetric analysis (TGA) showed an 84% 
weight loss (100 – 850 ºC at 5 ºC/min rate under Ar). The pronounced weight loss at 400 
ºC (70%) corresponded to the C-O functionalities of the PEG. The presence of carbon-
carbon double bonds from the PEG-HCC core was confirmed by the peak at 284.5 eV in 
the C(1s) region of the X-ray photoelectron spectrum (XPS). The strong signal at 286.0 
eV corresponded to the C-O bonds of the PEG chains. The Raman spectrum of the PEG-
HCCs clearly showed the G peak at ~1560 cm-1 which is associated with the planar 
configuration of sp2 bonded carbon in the graphitic domains of the PEG-HCCs core. 
Dynamic light scattering (DLS) measurements showed that a neutral pH the PEG-HCCs 
were 60 ± 0.8 nm in size (Figure 1A, Appendix A). 
Samples were analyzed for ROS scavenging effect following EPR and 
spectrophotometric assays described below. 
1.2.1. O2•- Scavenging Assay 
To analyze the O2•- scavenging property, the following reagents were mixed in a 2 
mL microcentrifuge tube: potassium phosphate buffer (PBS, 50 mM, supplemented with 
0.1 mM EDTA and 200 U/mL catalase;28 DEPMPO (20 mM); either PEG-HCCs (0.07 
mg/mL), PEG (0.07 mg/mL) or water; then KO2 dissolved in DMSO (~3.0 mM). The 
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final concentration of each reagent is indicated in parentheses. KO2/DMSO was prepared 
following a modified reported procedure.29,30  Briefly, 5 g of KO2 was suspended in 5 mL 
of anhydrous DMSO, stirred for 15 min, then centrifuged for 1 min. The supernatant 
phase contained the dissolved KO2. This procedure was repeated every 2 h and a quality 
control sample was taken every three runs in order to evaluate the decomposition of the 
KO2 mixture. Time = 0 was set as the time at which KO2 was added since it is the radical 
generator. Subsequently, the mixture was transferred to a capillary tube, sealed with 
Critoseal, and placed it in the EPR instrument. Due to the time required for sample 
transfer to the capillary tube and then to the EPR cavity, the earliest that the EPR 
spectrum could record was at 70 s. EPR measurements were recorded in a Bruker EMX 
spectrometer using the following parameters: 3315 G as center field, 200 G sweep width, 
microwave frequency 9.3 GHz, microwave power 40 mW, receiver gain 6.32×105, 
modulation frequency 100 KHz, modulation amplitude 0.50 G, signal channel conversion 
163.8 ms, time constant 327.7 ms, and sweep time 167.8 s.  
1.2.2.•OH Scavenging Assay  
To measure the •OH scavenging property, the following reagents were mixed in a 
2 mL microcentrifuge tube: PBS (50 mM, pre-treated with Chelex 100); DEPMPO (3.53 
mM); FeSO4·7 H2O (2.94 mM); either PEG-HCCs (0.06 mg/mL), PEG (0.06 mg/mL) or 
water; then the H2O2 (3.53 mM). The final concentration of each reagent is indicated in 
parentheses. Time = 0 was set as the time at which H2O2 was added, since it is the 
initiator of the reaction. Subsequently, the mixture was transferred to a capillary tube, 
sealed with Critoseal, and placed it in the EPR instrument. Due to the time required for 
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sample transfer to the capillary tube and then to the EPR cavity; the earliest that the EPR 
spectrum could be recorded was at 90 s. The concentration of Fe2+ also affects radical 
production, therefore several samples with different concentrations of the Fe2+ were run 
in order to select the concentration that produced the best EPR signal at 90 s. All EPR 
spectra obtained in this section were recorded using the same instrument, using the 
following parameters: 3315 G as center field, 200 G sweep width, microwave frequency 
9.3 GHz, microwave power 20 mW, receiver gain 7.1×104, modulation frequency 100 
KHz, modulation amplitude 0.50 G, signal channel conversion 163.8 ms, time constant 
327.7 ms, and sweep time 167.8 s. 
1.2.3. Spin Concentration Using Copper Standard 
Five different batches of PEG-HCCs (0.05 mg/mL) were frozen in small glass 
tubes using liquid nitrogen. The EPR spectra of the five samples and a CuSO4 (1 mM) 
standard solution were recorded at low temperature using the following parameters: 3310 
G as center field, 2000 G sweep width, microwave frequency 9.3 GHz, microwave power 
1 mW, receiver gain 7.1×103, modulation frequency 100 KHz, modulation amplitude 1.0 
G. Since the copper standard and the PEG-HCCs solutions were recorded under the same 
conditions, no corrections were necessary. The copper standard solution was 
supplemented with EDTA (10 mM) and NaClO4 (100 mM) to make a homogeneous Cu-
EDTA tetrahedral copper complex and uniform structure when frozen. 
1.2.4. Chelation Assay 
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PEG-HCCs (0.120 mg/mL) were stirred with FeSO4 (5.88 mM) for 3 h. The ratio 
between the PEG-HCCs and the FeSO4 were chosen based on the proportion that was 
used for EPR experiments. Then, the samples were dialyzed using a constant flow of DI 
water and a cellulose membrane (MWCO 5000 and MWCO 1000) for 48 h.  Finally, 
samples were diluted 5× in 1% HNO3, sterile-filtered using a 0.20 µm pore size 
membrane, and analyzed by inductively coupled plasma optical emission spectrometry 
(ICP-OES).  
1.2.5. Oxidation of ABTS by H2O2 catalyzed by HRP 
The ratios between H2O2 and PEG-HCCs for this experiment were based on the 
EPR experiments in which the Fenton reaction was used. ABTS (0.900 mM) was 
prepared in a citrate-phosphate buffer pH 5. H2O2 (0.300 mM), HRP (50 µg/mL) and 
PEG-HCCs (0.024 mg/mL) were prepared in PBS pH 7.4. H2O2, PEG-HCCs or PBS 
(control), and ABTS co-substrate were incubated for 10 min at room temperature. Then, 
the HRP solution was added in order to catalyze ABTS oxidation. The increase in the 
absorbance at 414 nm31 due to the ABTS•+ radical cation formation was monitored using 
a TECAN M-1000 plate reader.  The experiment was run in triplicate in a 96 well-plate. 
1.2.6. NO•  Scavenging Assay 
Oxyhemoglobin (HbO2; Fe+2, 8 µM based on heme content, ε425nm=125 M-1 s-1)32 
was dissolved in TEA buffer (50 mM, pH 7.5). The NO• solution was prepared by 
bubbling NaOH trap-purified 99.9% pure NO• gas (Matheson), through 10 mL of 
anaerobic TEA (50 mM, pH 7.5) for 10 min. A ~2 mM solution of NO• was obtained and 
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kept in a glass tonometer.33 The HbO2 and the PEG-HCCs were mixed in the quartz 
cuvette before initiating the reaction with the addition of the NO•. Therefore, if the PEG-
HCCs react with the NO• the absorbance difference of the reaction mixture will be lower 
than the control without PEG-HCCs because they would be preventing the formation of 
methemoglobin (metHb; Fe+3) by competing with HbO2 for NO•. The α (570 nm) and β 
(536 nm) peaks are hallmarks for control-HbO2 rather than metHb. Final metHb 
concentration was 9.7 ± 0.3 µM (ε401-411nm = 38 mM-1cm-1),32  and 0.02 mg/mL of both 
PEG-HCCs and PEG. The UV spectra were measured using a Hewlett-Packard diode 
array spectrophotometer model 8452.  
1.2.6.1. Anaerobic Sequential Stopped-Flow – Pre-Incubation of the NO• with PEG-
HCCs  
NO• radicals were incubated with the PEG-HCCs at three different aging time 
before mixing with HbO2 using the sequential mode of an Applied Photophysics model 
SX-18MV stopped flow instrument with rapid-scan diode array accessory. The 
instrument was located inside an anaerobic chamber model 110 V equipped with a gas 
analyzer model 10 (Coy Laboratory Products) for tracking the H2 and O2 levels. The 
chamber was filled with 10% H2 in N2.34 The following stock solutions were prepared 
using TEA (50 mM, pH 7.4): PEG-HCCs (0.08 mg/mL) in aerobic buffer, NO•  (20 µM) 
in anaerobic buffer and HbO2 (15 µM) in air-saturated buffer. Either buffer (control) or 
PEG-HCCs were incubated with NO• in a 1:1 ratio for 20 ms, 1 s, or 1 min in the aging 
loop after first mixing. This solution was then further mixed with HbO2 in a 1:1 ratio in 
the detector chamber. Note that 0.04 mg/mL was the concentration of the PEG-HCCs 
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when it was incubated with NO•, and 0.02 mg/mL when it was mixed with HbO2, thus an 
overall 4× dilution after two-stage mixing. 
1.2.7. Cytochrome c Assay 
The O2•- scavenging efficiency was also determined using the method described 
by Quick et al.35 Briefly, three reaction solutions were prepared, A-C. Solution A 
contained catalase (320 μL; 6000 U/mL), HX (320 μL; 10 mM solution in 30 mM 
NaOH), cytochrome c (755 μL; 1.95 mM solution in PBS), and 14.6 mL of PBS. 
Solution B consisted of XO (57 μL; 167.5 mU/mL in PBS) and PBS (743 μL). 
Additional B solutions were prepared with PEG-HCCs, replacing the PBS in volumes 
ranging from 1-743 μL. All solution B preparations were 800 μL, enough solution to run 
four replicates of each PEG-HCC concentration. Solution C included XO (57 μL; 167.5 
mU/mL in PBS), SOD (90 μL; 10200 U/mL in PBS), and PBS (653 μL) to allow 
determination of non- O2•--dependent reduction of cytochrome c (total volume 800 μL).  
The assay was performed in a 96-well plate with a final reaction volume of 325 μL per 
well. Each plate contained samples with the following conditions, using four wells for 
each condition: (1) a water blank (325 μL per well), (2) solution B without PEG-HCCs 
(the control reaction; 162.5 μL per well), (3) solution B with the PEG-HCCs (162.5 μL 
per well), and (4) solution C, containing SOD (162.5 μL per well). After all of the above 
solutions have been added to the plate, 162.5 μL of solution A was rapidly added to each 
well except for the water blanks. 2 min after the addition of solution A, a BIO-TEK 
Powerwave XS spectrophotometer (Winooski, VT) supported by SOFTmax Pro software 
(Molecular Devices, Sunnyvale, CA) was used to read the plate at 550 nm on a basic 
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kinetic protocol to measure absorbance every 45 s, for a total reaction time of 8 min. The 
reaction rate (OD/min) was determined and then plotted against the log of the 
concentration of the test compound. IC50 was determined using a nonlinear regression 
analysis (GraphPad Prism software version 5.0, La Jolla, CA).  
1.2.8. ONOO- Scavenging Assay 
Manganese dioxide (MnO2) was prepared by dissolving 8 g of KMnO4 in 50 mL 
water, forming a purple solution. 500 mL of 95% EtOH was slowly added, turning the 
mixture brown. The reaction was stirred overnight then vacuum filtered. The dark brown 
precipitate was washed with water and allowed to dry for several d.36 Separately, a 125 
mL aqueous solution containing 4 g NaNO2 was added to a 125 mL aqueous solution 
containing 7.5 mL 35% H2O2 and 2 mL 96% H2SO4. This mixture was immediately 
poured into 250 mL solution containing 12.5 g NaOH. To remove unreacted H2O2, MnO2 
was added to the final mixture and allowed to stand for 15 min. The concentration of 
ONOO- was determined to be 1.73 mM using the absorbance maximum at 302 nm (ε = 
1670 M-1 cm-1). ONOO- was portioned into 1.5 mL aliquots and frozen; during use, the 
ONOO- was kept on ice. Solutions of antioxidants (ascorbic acid, caffeic acid, PEG-
HCCs, trolox) were prepared at 0.100 mg/mL in phosphate buffer. Pyrogallol red was 
prepared at 5 mM in phosphate buffer. Assays were done in methacrylate cuvettes. 
Typically, 25 µL of pyrogallol red stock solution was added to the cuvette, followed by 
phosphate buffer, antioxidant (10, 30, 50, 100 or 200 µL) and finally ONOO- (the final 
volume was 1.5 mL). The cuvette was inverted several times after the addition of the 
ONOO-. The absorbance spectrum from 300 – 700 nm was measured. Each assay was 
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carried out in triplicate. Control samples were the pyrogallol red in the absence of 
antioxidant and ONOO-, as well as pyrogallol red in the presence of ONOO- without 
antioxidant. The absorbance change at 540 nm (ε = 2.4 × 104 M-1 cm-1) was used in 
inhibition calculations.36-38 
 
1.3. Results and Discussion 
In order to evaluate the scavenging capacity of the PEG-HCCs, EPR experiments 
were done using DEPMPO as a spin trap. DEPMPO forms stable adducts upon reaction 
with •OH3,4,39,40 and O2•-.6,41,42 O2•- will be generated using KO2 in DMSO30 and the •OH 
radicals will be generated by the Fenton reaction. The short lifetime of these radicals 
makes them undetectable at physiological conditions. However, reaction with a spin trap 
such as DEPMPO produces a relatively stable paramagnetic adduct that is spin active at 
room temperature.39,43  It was postulated that if the PEG-HCCs scavenge these radicals, 
the signal of the spin-adduct should be less intense when the PEG-HCCs are present. As 
this system was based on a competition reaction between the spin trap and the PEG-
HCCs, and the •OH and O2•- radicals have a very short life time; the spin trap must be 
present with the PEG-HCCs before the initiation of the reaction. In the case of O2•-, the 
buffer was supplemented with catalase to prevent the formation of •OH due to the 
reaction between H2O2 and traces of iron from the buffer. 
Figure 1.1 shows that the EPR amplitudes of the PEG-HCCs-treated systems were 
the lowest. This outcome can be explained in two ways: the PEG-HCCs could be 
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interacting with the radicals under study, or the radical-spin trap reaction could be 
uninhibited and the PEG-HCCs are interacting with the formed spin adduct. In order to 
rule out the second possibility, further experiments were performed. Notably, a peak 
~3315 G was detected that came from the PEG-HCCs during the O2•- scavenging 
experiments. The stability of the PEG-HCCs EPR signal will be also discussed later in 
this chapter. In order to compare the spin-adduct amplitudes associated with the O2•- 
scavenging, the EPR signal of the PEG-HCCs-treated system was corrected by 
subtracting the signal obtained from the PEG-HCCs alone (Figure A2, Appendix A). 
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Figure 1.1. EPR spectra at pH 7.4 and room temperature corresponding to the O2•- and 
•OH experiments. (A) EPR spectra obtained from the O2•- system or DEPMPO-OOH 
adduct. Spectra were recorded after 70 s of the KO2 addition. PEG-HCCs spectrum was 
corrected by subtracting the signals of the PEG-HCCs alone (Figure A2, Appendix A).  
(B) EPR spectra obtained from the •OH system or DEPMPO-OH. Spectra were recorded 
after 90 s of the H2O2 addition. No correction was necessary for the •OH scavenging 
experiments. 
         
The possible interaction between the PEG or PEG-HCCs with the spin-adduct 
was studied by adding them 10 s after the addition of KO2 or 20 s after the addition of 
H2O2. If either PEG or the PEG-HCCs are reacting with the spin-adduct, then a drop in 
the signal would be observed with respect to the signal of the PBS addition sample 
(control) at the corresponding experiment.  
As Figure 1.2 shows, there was no reduction in the signal and, therefore, no 
interaction between the PEG-HCCs and the adduct nor PEG and the adduct. In fact, for 
the O2•- experiments, there was a small increase in the signal intensity when the PEG and 
the PEG-HCCs were used. One plausible explanation was that the PEG-HCCs delayed 
the decomposition of the DEPMPO-OOH adduct. No signal related to DEPMPO-OOH 
adduct formation was observed when DEPMPO and PEG-HCCs were mixed in the 
presence of buffer and pure DMSO (Figure A3, Table A1, Appendix A), and so it can be 
concluded that the signal enhancement was not a result of the formation of O2•- by the 
PEG-HCCs or PEG under these conditions. The decomposition of DEPMPO-OH was 
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tracked for 30 min (Figure A5 and Figure A6, Appendix A). The results verified that 
neither the PEG nor PEG-HCCs promote decomposition of the DEPMPO-OH.  
The spin trap, DEPMPO, was mixed with the all the reagents that were used for 
both  O2•-  and •OH scavenging experiments and the EPR spectra was recorded with the 
purpose of verifying whether there was any significant signal that could affect the results  
(Table A1, Table A2, Figure A3, and Figure A7; Appendix A). Remarkably, a peak 
~3315 G was detected that came from the PEG-HCCs (the DEPMPO-OOH adduct does 
not have any signal at this magnetic field strength). This peak was not observed during 
the •OH radical evaluation because the microwave power and the receiver gain were 
lower (Figure A2 and Figure A8, Appendix A). Using a copper standard solution, it was 
determined that ~12% of the PEG-HCCs contain unpaired electrons. This value was 
obtained based on 5 different batches of PEG-HCCs, including batches that were 3 
months old; this indicates that they are exceedingly stable. The stability of the PEG-HCC 
EPR signal was followed at different concentrations and pHs at room temperature. A 
citrate buffer (50 mM, pH 4) was used for acidic conditions, PBS (50 mM, pH 7.4) for 
physiological conditions, and sodium borate buffer (50 mM, pH 9) for basic conditions. 
Time = 0 was set as the moment that the PEG-HCCs were mixed with the buffers. The 
EPR signal of the PEG-HCCs was stable after 5 h at physiological pH and pH 9. At pH 4, 
the EPR signal started decreasing (Figure A8, Appendix A). 
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Figure 1.2. EPR spectra obtained when PBS, PEG or PEG-HCCs were added after the 
DEPMPO-OOH (A) or DEPMPO-OH (B) adducts formed. (A) EPR spectra obtained 
from the O2•- system or DEPMPO-OOH adduct. (B) EPR spectra obtained from the •OH 
system or DEPMPO-OH adduct. No corrections were performed for any of the spectra.  
 
The O2•- specificity44 of the assay was confirmed by SOD, which is a fast enzyme 
to disproportionate O2•- to H2O2 and O2.45,46  The same procedure, as was used for the 
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added. As expected, dismutation of the O2•- was signaled by a decrease in the intensity of 
the 8-hyperfine line pattern of the adduct (Figure 1.3).  
 
Figure 1.3. EPR spectra of the samples treated with SOD instead of the PEG-HCCs. The 
dismutation of the O2•- radicals is being catalyzed by SOD causing a signal drop. (A) 
SOD 0.01 U/mL (B) SOD 0.10 U/mL (C) 1.00 U/mL (D) SOD 10.00 U/mL (E) PEG-
HCCs (0.07 mg/mL, which is the same concentration used in Figure 1.1A). Spectrum E 
was corrected by subtracting the EPR signal of the PEG-HCCs (Figure A4, Appendix A).  
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the value for the quenching effect was 10.0 U/0.07 mg of PEG-HCCs.  This value is 
similar to the total SOD activity value found in the entire rat brain, which is 13 U/mg of 
protein,35 and is higher than the SOD activity value reported for post-mortem human 
spinal cord, which is between 4-6 U/mg protein.35 It is noteworthy that similar SOD 
activity was achieved using 70 µg of PEG-HCCs or in other words 143 U/mg of the PEG-
HCCs. 
The antioxidant capacity of the PEG-HCCs was evaluated based on the EPR 
amplitude.6 Using the EPR amplitude located at 3278 G (the 2nd peak from the far left) 
for the O2•- system and 3308 G (the 4th peak from left to right) for the •OH system, PEG-
HCCs showed antioxidant activity of about 98% and 73% (Table 1) against O2•- and •OH 
radicals, respectively. O2•- is immediately produced when KO2 is added to the aqueous 
media, and it was concluded that the quenching effect was due to the direct reaction 
between the O2•- radicals and DEPMPO. For this reason, the k value related to the 
reaction between the PEG-HCCs and O2•- must be higher than 0.53 M-1s-1,47  which is the 
k value associated with DEPMPO-OOH formation. However, in the case of the •OH 
studies, two more considerations have to be studied: the PEG-HCCs may interact with 
iron or with H2O2, thereby preventing or decreasing the formation of •OH.  
 
Table 1. Relative % of antioxidant activity calculated from [% = ((Control amplitude – 
PEG-HCCs or PEG amplitude)/Control amplitude) ×100 %]. 
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  Average of 
the EPR 
amplitudea 
Standard 
deviation
Standard 
error 
Relative % of 
antioxidant 
activity 
 Control 28782 3833 2213 NA 
O2•- PEG 23774 6408 3700 13 ± 30c 
 PEG-HCCsb 433 320 185 98 ± 16c 
 Control 15242 3594 2075 NA 
•OH PEGd 12277 1488 1052 19 ± 5c 
 PEG-HCCs 4165 499 288 73 ± 20c 
Experiments were carried out in triplicate. Quality control sample was run every three 
samples. aEPR amplitude of the signal at 3278 G and 3308 G for the O2•- and •OH  
scavenging experiments, respectively. bAbsolute value. cError propagation from 
arithmetic calculations using standard deviations. dExperiment ran by duplicate. 
 
Iron chelation could be the mechanism that explains the antioxidant properties of 
the PEG-HCCs in the •OH scavenging experiments. Previously, the chelation or trapping 
ability of the PEG-HCCs was studied by two reported chelation assays: the ascorbic acid 
and the benzoate hydroxylation assay25 (Chapter 2). The ascorbate oxidation assay is 
based on the reduction of Fe3+ by ascorbic acid. The benzoate hydroxylation assay 
involves preventing the hydroxylation of the substrate by chelating iron, and therefore 
affecting the Fenton reaction. It was found that the PEG-HCCs oxidized ascorbic acid 
without any metal assistance, an indication of the oxidant properties of the PEG-HCCs in 
the presence of this type of compound. As the benzoate hydroxylation assay is based on 
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the Fenton reaction, no chelation information was obtained.25 That is the subject of 
Chapter 2. 
Additionally, the chelation of the PEG and PEG-HCCs after being mixed with 
FeSO4 was studied by ICP-OES using the same proportions that were employed for the 
former EPR experiments. Figure1.4A shows that only 14.8 ± 1.9% of the iron was 
contained by the PEG-HCCs. This iron retention is due mostly to the PEG chains of the 
nanoparticle since experiments of the PEG-treated system showed that they were able to 
retain 11.0 ± 0.3% of the iron after 48 h dialysis. These results indicate that the iron 
chelation is not the main factor that causes the signal loss during EPR experiments. 
Hence, there is no significant pre-antioxidant property in the PEG-HCCs due to iron-
chelation.  
As was mentioned earlier, the drop in the EPR signal of the PEG-HCC-treated 
system might be caused by the interaction between H2O2 and PEG-HCCs because the 
interaction might prevent the •OH formation. This possible interaction was investigated 
following the production of the radical cation ABTS•+from the H2O2 oxidation of ABTS 
in the catalyzed by HRP enzyme by UV/Vis. The increase absorbance at 414 nm was 
used to monitor the reaction.31 PEG-HCCs were incubated with H2O2 using the same 
ratio that was used for the EPR experiments. Figure 1.4B illustrates that only 5% of the 
H2O2 interacts with the PEG-HCCs. Again, the drop in the signal could be caused by the 
reaction between the radical cation ABTS•+and PEG-HCCs. Figure 1.4B showed that 
there was no reaction between the PEG-HCCs and the product cation. Since only 5% of 
the H2O2 interacts with the PEG-HCCs, it is concluded that the loss of intensity in the 
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EPR signal was due principally to the reaction between the PEG-HCCs and the •OH 
generated. Thus, the rate constant of this reaction must be higher than the rate constant of 
the DEPMPO-OH formation, which is 7.8 ×109 M-1 s-1.48   
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Figure 1.4. Interaction between the PEG-HCCs and Fenton reaction reagents. (A) % of 
Fe retained by the PEG-HCCs detected by ICP-OES. Either PEG-HCCs or PEG were 
mixed with FeSO4 for 3 h and then dialyzed in a constant water flow for 48 h. “Fe max” 
is the maximum iron amount used in the experiment (no dialysis). “Fe min” corresponds 
to the amount of iron remaining inside the membrane after being dialyzed for 48 h. (B) 
ABTS oxidation catalyzed by HRP followed by UV/Vis analysis. The absorbance of the 
oxidation product, ABTS•+, was measured at 414 nm. Only ~5 % of the H2O2 interacts 
with the PEG-HCCs.  No interaction between the PEG-HCCs and the cation product was 
observed since PBS/ABTS•+ and PEG-HCCs/ABTS•+ systems behave equally when PBS 
or PEG-HCCs were added after the cation was formed. Experiments were run in 
triplicate.  
The ability of the PEG-HCCs to quench ROS extracellularly was also evaluated 
by exposing the PEG-HCCs to O2•- generated by the metabolism of HX/XO.  The 
concentration of the superoxide anion was determined using a microplate assay35 based 
on the SOD-inhibitable reduction of ferricytochrome c,49 and followed as absorbance at 
550 nm. It has been suggested that the carbon cores of the PEG-HCCs are responsible for 
their peroxyl radical scavenger properties,25 and so their ability to inhibit the reduction of 
cytochrome c was calculated on this basis. PEG-HCCs were effective antioxidants and 
they achieved inhibition equivalent to half of the positive control (IC50), which was a 
large excess of SOD. The IC50 value of the PEG-HCCs was 0.20 ± 0.01 mg/mL (Figure 
1.5). The IC50 concentration for the PEG-HCCs is well within the concentration range 
shown to be acutely non-toxic.24,26 
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can be spectrophotometrically monitored because the change in the oxidation state of iron 
from +2 to +3 causes a blue shift23 of the Soret absorption peak of the hemeprotein from 
415 nm (HbO2)52  to 401 nm (metHb).32,52,53 In general, NO• can be indirectly determined 
in aerobic aqueous systems by the production of metHb, which is estimated by the 
absorbance differences (ΔA401-411nm).32,53 HbO2 and the PEG-HCCs were mixed in a 
quartz cuvette before initiating the reaction by addition of NO•. If the PEG-HCCs and 
HbO2 react with the radical at comparable rate, the absorbance difference will be lower 
than in the absence of PEG-HCCs, as the PEG-HCCs would be preventing the formation 
of metHb; the α (~570 nm) and β (~536 nm) peaks would show intensities similar to the 
control-HbO2 spectrum instead of the metHb spectrum. Figure 1.6 indicated that neither 
the absorbance of the HbO2 nor metHb was affected by the presence of the PEG-HCCs at 
low concentrations (0.02 mg/mL). However, when concentrations of 0.08 mg/mL are 
used, the heme group was destroyed. PEG-HCC concentrations of 0.04 mg/mL are also 
suitable for this assay (data not shown). Importantly, in vivo, HbO2 is encapsulated in red 
blood cells,54 so there is no evidence that suggests that the PEG-HCCs destroy HbO2 in 
vivo. Figure 1.7 shows the difference spectrum of metHb and HbO2 in the absence (blue) 
and presence of the PEG-HCCs (0.02 mg/mL, red). As the difference between the ΔA401-
411nm values of the control and the ΔA401-411nm values of the PEG-HCCs differs in less 
than 10% (experimental error), it can be concluded that either the PEG-HCCs are not 
quenching the NO•  radicals or that the reaction rate between the NO• and the PEG-HCCs 
is much slower than the NO• and HbO2 reaction.  
26 
 
 
Figure 1.6. Optical spectra of the starting material (HbO2) and final product (metHb) 
after being mixed with H2O (blue set) or several concentrations of PEG-HCCs (red and 
green sets). Experiments were carried out in triplicate. The arrow indicates the blue shift 
of the Soret peak. α (~550 nm) and β (~590 nm) peaks of the HbO2 decrease in intensity 
during conversion to metHb. Low concentration of the PEG-HCCs (0.02 mg/mL) does 
not decompose the HbO2 (red set), however, higher concentrations of the PEG-HCCs 
(0.08 mg/mL) destroy the heme group (green set).   
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Figure 1.7. Difference spectrum of metHb and HbO2 in the absence (blue) and presence 
of the PEG-HCCs (0.02 mg/mL, red). The difference between the ΔA401-411nm values of 
the control and the ΔA401-411nm values of PEG-HCCs treated system is lower than the 
experimental error. The experiment was done in triplicate. Control or PBS treated (blue, 
— ). PEG-HCCs treated (red, ----).  
 
In order to compare the rates of reaction between both PEG-HCCs and HbO2 with 
NO•, the NO• radicals were incubated with the PEG-HCCs at three different time points 
before the addition of the HbO2.34 Either buffer (control) or PEG-HCCs were incubated 
with NO•  in a 1:1 ratio for 20 ms, 1 s, or 1 min in the aging loop of the sequential 
stopped-flow. This solution was then mixed with HbO2 in a 1:1 ratio in the detector 
chamber. Note that 0.04 mg/mL was the concentration of the PEG-HCCs when it was 
incubated with NO•, and 0.02 mg/mL when it was mixed with HbO2. Figure 1.8 as well 
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as Figure A9 and Figure A10 (Appendix A) demonstrate that there is no interaction 
between the PEG-HCCs and NO• radicals even after 1 min of incubation. Further, they 
show that NO•  radicals do not decay or decompose in these conditions. Since there was 
no effect with the PEG-HCCs, no experiments with PEG alone were performed as it is 
deemed unnecessary. 
 
 
Figure 1.8. Difference spectrum of metHb and HbO2 in the absence (blue) and presence 
of the PEG-HCCs (red) after being incubated with NO• for 1 m. The difference between 
the ΔA401-411nm values of the control and the ΔA401-411nm values of PEG-HCCs treated 
system is lower than the experimental error. The experiment was carried out in triplicate. 
PBS treated (blue, — ) and PEG-HCCs treated (red, ----). 
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NO• reacts quickly with O2•- forming ONOO-. Thus, the interaction between the 
ONOO- and the PEG-HCCs  was also studied using the ONOO--induced quenching of the 
dye pyrogallol red. It was hypothesized that the PEG-HCCs would inhibit the quenching 
of the dye if they react with ONOO-. Ascorbic acid, caffeic acid and trolox all inhibit the 
quenching reaction in a manner consistent with reported results,38 but PEG-HCCs had no 
effect (Figure 1.9). Bearing in mind that NO• is constantly produced in vivo and is freely 
diffusible, production of ONOO- is more likely to occur in regions in which there is a 
high local concentration of O2•-. As was previously demonstrated, PEG-HCCs do 
scavenge O2•- and this upstream scavenging will necessarily decrease the amount of 
ONOO- produced in vivo.  
 
Figure 1. 9.- Inhibition of the pyrogallol red decomposition assay. (▲, blue) Caffeic 
acid.  (♦, green) Ascorbic acid. (■, red) Trolox.  (●, black) PEG-HCCs.  
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1.4. Conclusions 
In summary, it has been demonstrated that PEG-HCCs quench ROS. 73% of •OH 
species were scavenged by the PEG-HCCs with a k comparable with the DEPMPO-OH 
formation k (7.8 ×109 M-1 s-1).48 In this case, while iron chelating capability and the 
interaction of H2O2 with the PEG-HCCs might be small contributing factors to the 
quenching, they are not the main features responsible for the antioxidant properties 
observed. Remarkably, 98% of O2•- species were quenched by the PEG-HCCs with a k 
higher than 0.53 M-1s-1, which is the k corresponding to the DEPMPO-OOH formation.47 
Amazingly, based on the EPR measurements, 1 mg of the PEG-HCCs has the similar 
effect of 143 U/mg of SOD, which is 28 times the average value of the SOD activity 
reported for post-mortem human spinal cord.35 In addition, PEG-HCCs were inert to NO•. 
These scavenging properties make the PEG-HCCs a highly suitable antioxidant treatment 
during ischemic/reperfusion events in which the production of O2•- dramatically increases 
and the levels of NO• might decrease.56 Therefore, a NO•-inert scavenger will help to 
stabilize the NO• levels, thereby, improving the vascular homeostasis and contributing to 
the healing process. Finally, PEG-HCCs were also inert to ONOO-.  However, the 
production of ONOO- is more likely to occur in regions in which there is a high local 
concentration of O2•-. Thus, a decrease in the levels of O2•- as we show here will also 
decrease the levels of ONOO-. 
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1.7. Experimental Contributions 
I performed and analyzed the data related to EPR, chelation, oxidation of the 
ABTS, and oxo-hemoglobin experiments. Dr. Berka assisted with the EPR and 
hemoglobin experiments. Errol L. Samuel and Austin Potter worked on the inhibition of 
the pyrogallol red decomposition assay and characterization of the PEG-HCCs. Dr. 
Bitner performed the cytochrome c experiments.  
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Chapter 2 
                    Design of Poly(ethylene 
glycol)-functionalized Hydrophilic 
Carbon Clusters for Targeted Therapy 
of Cerebrovascular Dysfunction in Mild 
Traumatic Brain Injury 
This chapter was entirely copied from the reference #1 of this section 
 
2.1. Introduction 
Reactive oxygen species (ROS) are an essential component of many regulatory 
processes in living organisms. Normally, they are continuously generated, transformed 
and consumed inside biological systems in which timing and location of these reactive 
species are firmly regulated2. Oxidative stress and vascular dysfunction is a prominent 
feature of traumatic brain injury (TBI),3-5  in particular when accompanied by secondary 
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insults such as hemorrhagic hypotension.6,7  Cerebrovascular dysfunction is evident even 
in mild TBI (mTBI) and if complicated by hypotension, causes both structural lesions and 
behavioral dysfunction.8  In the case of an acute injury, there is both an acute elaboration 
of superoxide radicals7  and an extended period of oxidative stress as the initial injury 
sets off a cascade that can last for days.9  Consequently, antioxidant therapies have been 
investigated for treating TBI. Extensive research has explored using small molecule 
antioxidants, such as phenyl N-tert-butyl nitrone (PBN) and tirilazad mesylate, or 
stabilized enzymes, such as PEGylated superoxide dismutase (PEG-SOD), to combat 
oxidative stress.10,11 Unfortunately, none of these potential therapies has shown efficacy 
in clinical trials,11,13 and there are no Food and Drug Administration-approved 
antioxidant therapies for these conditions.14   
The generation of oxidative radicals is increased after a TBI. Secondary injuries 
such as hypotension (low blood pressure), a major contributor to poor outcome in TBI, 
are additional sources of oxidative radical generation with several bursts of superoxide 
documented throughout the course of TBI and hypotension and reperfusion.7  Moreover, 
our previous work has shown that PEG-SOD has only small and transient effects.7 
Therapies to address oxidative stress must, therefore, be rapidly effective and able to 
address the site of radical generation or its consequences at a clinically realistic time 
point.  There is little evidence that conventional antioxidants can achieve these goals. 
Hence, there is a need to find new classes of biologically compatible antioxidants. 
Nanoparticles are an emerging group of such materials.15  Nanoparticles have markedly 
different biodistribution and metabolic profiles than small molecules or enzymes, and 
they also may afford improved in vivo efficacy.  
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We previously showed that single-walled carbon nanotubes (SWCNTs) and 
ultrashort SWCNTs are antioxidants, as measured by the oxygen radical absorbance 
capacity (ORAC) assay.15  We have recently developed another class of biologically 
compatible carbon-based nanovectors, poly(ethylene glycol)-functionalized hydrophilic 
carbon clusters (PEG-HCCs).16,17 PEG-HCCs can be readily functionalized with 
antibodies for targeted drug delivery. These PEG-HCCs can be loaded with hydrophobic 
drugs, and when mixed with an antibody, a noncovalent formulation capable of targeted 
drug delivery in vitro is formed.18,19 PEG-HCCs are approximately 50 nm in size at 
neutral pH based on dynamic light scattering (DLS) and have a zeta potential of -23.04 
mV at pH 7.0,  which is evidence for the negatively charge surface of the nanoparticle. 
This potential also indicates that the PEG-HCCs will flocculate with time. However, the 
PEG-HCCs can be easily re-suspended after vortexing the mixture for 5 min. Also 
importantly, ~ 94% of the PEG-HCC is constituted by PEG,18 which is a non-ionic 
hydrophilic polymer approved for certain uses by the Food and Drug Administration 
(FDA) that is well tolerated clinically20-23 with the additional benefit that polyethylene 
glycol can protect and restore the integrity of cell membranes.24-26 Our preliminary 
toxicity and biodistribution studies indicate that these PEG-HCCs nanoparticles are not 
acutely toxic in normal mice, with no evidence of chemical or pathological damage to 
major organs and with a circulating half life of 2-3 hours.18  
Here we report the in-vitro characteristics of PEG-HCC’s designed specifically to 
address cerebrovascular dysfunction that accompanies TBI.  We show that PEG-HCCs 
possess antioxidant activity that is potent enough to reduce oxidative stress in vitro 
following injury that its antioxidant mechanism does not involve metal chelation, and can 
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be targeted to a model of injured brain endothelial cells expressing p-selectin antigen. P-
selectin expression is increased in brain endothelial cells following traumatic brain 
injury,27 and possibly systemically depending on the trauma mechanism.  These results 
suggest that targeted PEG-HCCs are potential therapeutics for oxidative stress-induced 
cerebrovacular dysfunction from mTBI. 
 
2.2. Experimental Procedures 
For all these experiments, PEG-HCCs were prepared as previously described and 
sterile filtered using a 0.20 µm pore size membrane.18    
2.2.1. ORAC Assay  
 The following solutions were prepared daily: phosphate buffer at pH 7.4 (PBS, 
75 mM), fluorescein sodium salt (0.1 µM), α,α’-azodiisobutyramidine dihydrochloride 
(AAPH, 0.15 M), racemic 6-hydroxy-2,5,7,8-tettramethylchromate-2-carboxilic acid 
(trolox, 400 µM). The experiment was carried out in a 96-well plate and each sample was 
analyzed by triplicate as shown below (Table 3.1). After the addition of the fluorescent 
probe or PBS and sample (1st step) to the assigned wells, the plate was incubated at 37 ºC 
for 15 min in a TECAN plate reader. Then, the ice-cold AAPH or PBS was added (2nd 
step) and the fluorescent intensity at 530 nm (485 nm excitation) was measured every 
minute for 2 h. Data were analyzed as follow: control 2 (background) was subtracted 
from the assay and control 1. The assay well results were divided by the control 1 and the 
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area under the curve (AUC) was determined by equation 1.  trolox mass equivalents 
(TME) were determined by equation 2. 18,28-34 
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            (Equation 2.2) 
 
Table 2.1. ORAC Assay design 
 
1st  step 2nd step 
Assay 
120 µL 
of Fluorescein 
20 µL 
of Sample 
60 µL 
of AAPH 
Control 1 
(no AAPH) 
120 µL 
of Fluorescein 
20 µL 
of Sample 
60 µL 
of PBS 
Control 2 
(no Fluorescein) 
120 µL 
of PBS 
20 µL 
of Sample 
60 µL 
of AAPH 
Trolox and phosphate buffer (blank) were run as samples. At least 3 standards of trolox 
were run for the calibration curve.  
 
2.2.2. Chelation Assays 
It has been found that iron forms deposits in patients with mTBI, this iron 
accumulation can be involved in the pathology of a TBI as one of the major secondary 
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events.35-37 Furthermore, free iron causes oxidative stress when reacts with hydrogen 
peroxide to form hydroxyl radicals (Fenton reaction), and with lipids to produce alkoxy 
and peroxyl radicals (lipid peroxidation). Iron chelation therapy has been proposed in 
order to diminish the oxidative process.36 Nonetheless, it is important to understand the 
effect that the chelator might have on the catalytic cycle of Fe+2/Fe+3 process. In order to 
explore the behavior of the iron when combined with our nanoparticles, we ran the 
following iron chelator assays: benzoate hydroxylation and ascorbate oxidation.  
Ascorbic acid (cat # AC40147), benzoic acid (cat # AC22180), iron(II) sulfate 
heptahydrate (cat # AC42373), iron(III) chloride hexahydrate (cat # AC21709), and the 
disodium  ethylenediamine tetraacetate (EDTA, cat # E4884) were obtained from Fisher 
Scientific.   Deferoxamine mesylate salt (DFO, cat# D9533) was obtained from Sigma-
Aldrich. 
2.2.2.1. Benzoate Hydroxylation 
This assay is based on the hydroxylation of benzoate when exposed to iron and 
H2O2, producing the fluorescent compounds 2,3,4-trihydroxybenzoate (308 nm excitation 
and 410 nm emission)38-41 with the major products 2-hydroxybenzoic acid salt or salicylic 
acid salt at pH 7.4. In brief, the following solutions were freshly prepared before each run 
according to reported procedures:42 benzoic acid (3 mM, recrystallized from hot water),  
FeCl3 (1.80 mM), FeSO4 (1.80 mM), methoxypolyethylene glycol amine polymer  (PEG 
MW 5,000, 0.02 mg/mL) and PEG-HCCs (0.02 mg/mL). EDTA (0.60 mM) and DFO 
(0.60 mM) were used as the positive and negative control, respectively.  The benzoic acid 
was incubated at room temperature for 1 h in the phosphate buffer (pH 7.4) with 5 mM of 
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H2O2 and the ferric or ferrous iron salt, in the presence of one of the controls or the PEG-
HCCs. The reaction was started by the addition of any the iron salts and kept in dark. 
Salicylate was used to determine the quenching effect of the materials.42  
2.2.2.2. Ascorbate Oxidation  
This assay was performed in a similar way to that described previously.43-47  
Briefly, the following solutions were prepared prior to each experiment:  ascorbic acid 
(0.1 mM), FeCl3 (0.60 mM), potassium phosphate buffer (50 mM, pH 7.4, cleaned with 
Chelex resin), EDTA (0.02 mg/mL previously recrystallized three times from hot water), 
DFO (0.02 mg/mL), and PEG-HCCs (0.02 mg/mL). The ascorbate absorbance at 265 nm 
was measured after 1, 5 and 30 min using a TECAN plate reader.  
2.2.3. Cell Culture 
Murine brain endothelioma (bEnd.3, CRL 2299, ATCC, Manassas, VA) were 
cultured in DMEM-F12 (50:50) with 4 mM L-glutamine media, supplemented with 10% 
fetal bovine serum (both from HyClone) and 1% Pen Strep (+10,000 u/mL 
penicillin/+10,000 µg/mL streptomycin, from GIBCO). During the second week, between 
the 4th and 6th passage, cell experiments were performed. 
2.2.3.1. P-selectin Targeting 
bEnd.3 cells were grown on glass covers to 60-70% confluence in 6 well plates. 
P-selectin-targeted PEG-HCCs (ps/PEG-HCCs) were synthesized by adding 0.01 µg anti-
p-selectin antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA) to 0.49 µg PEG-
HCCs and incubating at RT for 1 h. The antibody possesses hydrophilic and hydrophobic 
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domains that allow the nanovector to sequester it. The bEnd.3 cells were treated with 
histamine (20 µM) to induce p-selectin expression or woth 1X PBS (histamine diluent) as 
a control.48 After a 15 min incubation at 37° C, the cells were treated with vehicle (1X 
PBS), PEG-HCCs (0.49 µg), or ps/PEG-HCCs. Cells were incubated for 15 min and then 
washed twice and fixed with methanol. Cells were washed and stained with anti-PEG 
(Epitomics, Burlingame, CA) and anti-p-selectin antibodies (Santa Cruz Biotechnology 
Inc, Santa Cruz, CA). After washing, cells were probed with fluorescent secondary 
antibodies to the anti-PEG and anti-p-selectin antibodies (Invitrogen, Carlsbad, CA). 
Glass covers were mounted on slides and fluorescent images were captured on an 
epifluorescent microscope.    
2.2.3.2. Intracellular Superoxide Cell Culture Model 
bEnd.3 cells were cultured to 50-80% confluence in 6 well plates in 2 mL of 
culture media. The cells were treated with vehicle (1X PBS), PEG-HCCs, ps/PEG-HCCs, 
or p-selectin antibody alone (same concentration as found in ps/PEG-HCCs). After 15 
min, the cells were treated with 10 µL of 2 mM Antimycin A or 10 µL ethanol (control). 
Antimycin A has been shown to induce intracellular superoxide radical production.49 The 
cells were incubated at 37 °C for 40 min, at which point 2 µL of 10 mM dihydroethidine 
(DHE)49 (in 50%/50% DMSO/1X PBS) was added to wells or 50%/50% DMSO/1X PBS 
(control). DHE reacts with ROS to form 2-hydroxyethidium, which possesses red 
fluorescence when excited near 480 nm; thus, the increase in red fluorescence is 
proportional to the ROS in the sample.50 The cells were then placed on ice, trypsinized, 
and washed twice. Cells were subsequently counted and stained with SytoxRed (viability 
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stain). 10,000 cells were analyzed per treatment group using the TXRED channel (DHE) 
and SytoxRed to assess cell viability.  A higher dose of Antimycin A was also studied to 
confirm that PEG-HCC’s were able to protect against oxidative cell death (Appendix B, 
Figure B1).   
 
2.3. Results and Discussion 
2.3.1. ORAC Assay 
The antioxidant capacity of the PEG-HCCs was compared by ORAC to known 
antioxidants vitamin C, caffeic acid, and catechin. ORAC measures antioxidant capacity 
by the ability of a substance to inhibit the loss of fluorescence caused by the oxidation of 
a fluorescent dye by peroxyl radicals formed during the thermal decomposition of the 
AAPH,28-34 without the assistance of any metal.32 The linear relationship between the net 
area and antioxidant concentration was evaluated by using a set of trolox and PEG-HCCs 
standards (Appendix B, Figure B2 - Figure B4). Table B.1 (Appendix B) summarizes the 
correlation coefficient, slope, and intercept of the trolox standard curves obtained in each 
run. The assay was consistent for all concentrations tested. For comparison and TME 
calculations, the concentrations of vitamin C, caffeic acid, catechin, trolox, and PEG-
HCCs were kept constant at 1.6 µg/mL (Figure 2.1A and Table B2 of Appendix B). 
According to these results, PEG-HCCs showed higher antioxidant capacity than vitamin 
C, but lower than catechin and caffeic acid (Figure 2.1B). This range of antioxidant 
potential demonstrates that the PEG-HCCs likely possess enough antioxidant capacity to 
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be biologically relevant. Although the antioxidant mechanism is not fully known, given 
the nature of the carbon core, we hypothesize that this is due to the conjugated domains 
in the carbon core. When these domains receive two RO· species, two carbon–carbon pi-
bonds will be lost but two new C–O sigma bonds and one new C–C pi bond will be 
formed without any radical species remaining (Figure 2.2). 
 
 
Figure 2.1. Typical fluorescence decay and calibration curves obtained. (A) Fluorescence 
decay curve obtained during the vitamin C, caffeic acid, catechin, and PEG-HCCs 
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evaluation.  (B) Curve C represents the TME values corresponding to the different known 
antioxidants and carbon nanoparticles respectively. Trolox is the reference compound 
(TMEtrolox=1). 
 
 
Figure 2.2.  Suggested radical scavenging mechanism. Two additions of RO· result in the 
loss of two C–C pi-bonds and the formation of two new C–O sigma bonds and one new 
C–C pi bond without any radical species remaining. 
 
2.3.2. Chelation as a Potential Mechanism 
Iron accumulation in the pathology of TBI has been reported for mice51 and 
humans35 based on magnetic resonance imaging. It is known that Fe+2 and Fe+3 form lipid 
alkoxy radical and peroxyl radicals respectively, which induced the production of the 
neurotoxic aldehydes.15 Therefore, it is important to determine if the nanoparticles 
stimulate the iron redox cycle (similar to EDTA) or inhibit it (similar to DFO). In order to 
assess this property, chelation assays were performed.   
2.3.2.1. Benzoate Hydroxylation  
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The iron chelating assay was used to evaluate the antioxidant capacity of PEG-
HCCs when is exposed to hydroxyl radicals produced by the reaction between iron and 
H2O2. In this assay, we monitored the oxidation of benzoate to salicylate by hydroxyl 
radicals produced by the Fenton reaction.  To ensure that this measurement would be 
robust, sodium salicylate (SA) was mixed with PEG or PEG-HCCs every time that the 
experiment was run, in order to estimate how the fluorescence intensity was affected by 
the nanomaterial or the polymer, and then we proceeded to correct it (Figure 2.3A). In 
general, it was observed that PEG-HCCs quench about ~20% of the fluorescence and the 
PEG can enhance the fluorescence up to ~10%. In the actual assay, EDTA and DFO were 
included as positive and negative controls, respectively. PEG-HCCs decreased the 
hydroxylation process as well as DFO in comparison to the case in which no chelating 
agent was added (Figure 2.3B and 2.3C) for both iron systems. Interestingly, both PEG-
HCCs and PEG reduced the hydroxylation of benzoic acid when the highest 
concentration of Fe+2 was used.  We speculate that this could be due to the radical 
scavenger capacity of the carbon core (Figure 2.2), the degradation of the polymer chains 
as previously reported,52-54 or both.   Iron/PEG-HCCs systems do not induce the Fenton 
reaction.  
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Figure 2.3. Benzoate hydroxylation assay. (A) Typical fluorescence quenching 
evaluation of the PEG-HCCs, PEG chains, and SA obtained in each experiment. PEG-
HCCs can decrease the fluorescence intensity about ~20% while PEG can enhance it up 
to ~10% in average. These estimations were used for corrections purposes.  (B) Benzoate 
hydroxylation induced by Fe+2 in the presence of EDTA, DFO, PEG-HCCs and PEG. 
PEG-HCCs and DFO inhibit the hydroxylation process at a similar level.  In fact, PEG 
also prevents the hydroxylation at the highest concentration of the iron. (C) Benzoate 
hydroxylation induced by Fe+3.  Again, PEG-HCCs and DFO inhibit the hydroxylation 
process at a similar level.  PEG-HCCs do not induce the Fenton reaction. The 
concentrations used were 0.60 mM for EDTA and DFO and 0.02 mg/mL for PEG-HCCs 
and 0.02 mg/mL for PEG.  
 
2.3.2.2. Ascorbate Oxidation  
Ascorbic acid is able to serve as a donor antioxidant in free radical-mediated 
oxidative processes.  But it is also able to reduce redox-active metals such as copper and 
iron, thereby increasing the oxidant properties of those metals. In general, at low 
concentrations, ascorbic acid is prone to be a pro-oxidant and at high concentrations 
serves as an antioxidant.45 In this assay, the oxidation of ascorbic acid by Fe3+ is 
monitored in the presence or absence of substances. EDTA again enhanced the oxidative 
activity of the Fe+3 while DFO inhibited it. We tested the PEG-HCCs in this system to 
determine if their antioxidant capacity could be due to interactions with trace iron 
content, and if there is such an interaction, the oxidation of the ascorbic acid should be 
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inhibited.  We followed the oxidation of the ascorbic acid after 5 min and 30 min of metal 
addition (Figures 2.4A and 2.4B). And, we found that in this system the PEG-HCCs 
function as potent oxidants, regardless of the presence or absence of Fe3+. PEG-HCCs 
and ascorbic acid show similar pro-oxidant and antioxidant behaviors; the difference is 
that for PEG-HCCs, no metal participation is necessary.    
 
 
 
Figure 2.4. Oxidation of the ascorbic acid after (A) 5 min and (B) 30 min of metal 
addition. Trace of metal was likely present in the buffer as there were different 
absorbance values for EDTA and DFO compared to no chelator when no extra iron was 
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added. Overall, these results show that PEG-HCCs in the presence of a reductant such as 
ascorbate function as potent oxidant, regardless of the presence or absent of Fe+3. 
 
2.3.3. Targeted Binding of PEG-HCCs to Cultured Brain Endothelial Cell Line  
Having demonstrated that the PEG-HCCs possessed antioxidant capacity in cell 
free systems, but that it could be dependent on the presence of reductants such as 
ascorbate, we evaluated if the PEG-HCCs could be targeted to cultured brain endothelial 
cells and if they could also alleviate oxidative stress in a biological system. A brain 
endothelial cell line was chosen because endothelial dysfunction is apparent even after 
mTBI,55 and in the case of mTBI, there is minimal detectable brain injury and functional 
deficits unless hypotension is superimposed.8 bEnd.3 cells were treated with histamine, 
which is known to rapidly induce the expression of p-selectin. PEG-HCCs were targeted 
to p-selectin. In endothelial cells, p-selectin, a cell adhesion molecule is involved in 
recruiting leukocytes to sites of inflammation and injury. P-selectin is rapidly expressed 
on endothelial cells following activation by histamine.49 In this experiment, we treated 
cells with histamine or 1× PBS to induce p-selectin expression (Figure 2.5). After 15 min, 
the cells were treated with 1× PBS, PEG-HCCs, or ps/PEG-HCCs. The cells were 
incubated for another 15 min and after washing and fixing, they were stained with 
fluorescent antibodies for the presence of PEG to detect PEG-HCCs using an anti-PEG 
antibody (green), anti-p-selectin antibody(red) to detect p-selectin, and DAPI (nuclear 
stain; blue).  In the cells that are not stimulated by histamine, there is little binding 
apparent with the p-selectin targeted PEG-HCCs.  However, there was a dramatic 
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increase in binding with the targeted p-selectin antibody bound PEG-HCCs after 
stimulation by histamine (Figure 2.6, bottom panel).  This experiment demonstrates 
greatly enhanced binding of the targeted PEG-HCCs to endothelial cells in a model that 
induces expression of a protein, p-selectin.  
 
Figure 2.5. b.End3 cells express p-selectin when stressed by histamine. Cells were 
treated with histamine or the diluent 1× PBS, fixed, and stained for the presence of p-
selectin (green) and DAPI (blue).  There was considerably enhanced binding of p-selectin 
antibody following histamine treatment, confirming increased expression of p-selectin.  
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Figure 2.6. b.End3 cells oxidatively stressed by treatment with histamine or 1× PBS were 
exposed to vehicle, PEG-HCCs or the targeted variant ps/PEG-HCC and stained for the 
presence of PEG (green) and DAPI (blue). There is considerably enhanced binding of 
anti-PEG antibody following histamine treatment indicating enhanced binding of the 
ps/PEG-HCCs to stimulated b.End3 cells. 
 
We then evaluated whether applying the targeted p-selectin antibody to the PEG-
HCCs would reduce its antioxidant ability.  We tested the protective capacity of the 
nanoparticles by stressing the cells with Antimycin A and determining the effectiveness 
of the native or antibody bound PEG-HCCs at reducing levels of oxidative radicals. The 
level of oxidative stress was measured by DHE fluorescence.  An increase in 
fluorescence is proportional to oxidative stress and is roughly proportional to superoxide 
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levels, although not specific under all conditions.47  In this study, we replicated the ability 
of the PEG-HCCs to reduce DHE fluorescence56 even when applied after the Antimycin 
A, and in this study found that ps/PEG-HCCs reduced the level of DHE fluorescence to 
comparable levels as non-antibody bound PEG-HCCs, and to background (DHE) (Figure 
2.7).  By comparison, p-selectin antibody by itself had no significant effect on DHE 
fluorescence.   
 
 
Figure 2.7. PEG-HCCs and targeted ps/PEG-HCCs effectively reduce intracellular 
oxidative stress. Antimycin A was used to induce intracellular superoxide production. 
DHE mean fluorescence intensity (indicative of oxidative stress) was measured in cells 
treated with Antimycin A to induce superoxide production (mean of 5 separate 
experiments). Results are given as % control (DHE + Antimycin A, black bar) to account 
for minor differences in DHE concentrations and laser fluctuations. Untargeted (solid 
grey) PEG-HCCs and targeted ps/PEG-HCCs (striped grey) were effective at reducing 
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DHE fluorescence after Antimycin A treatment, while treatment with a similar amount of 
pselectin antibody in the absence of PEG-HCCs (striped white) was not effective. 
 
These results indicate that PEG-HCCs possess antioxidant capacity sufficient be 
biologically relevant and further, the mechanism does not involve chelation. They were 
effective in cultured brain endothelial cells in vitro when administered following 
administration of a mitochondrial toxin that induces oxidative stress.  They could also be 
readily targeted to oxidatively stressed brain endothelial cells, and when functionalized 
for targeting, they retained the ability to alleviate oxidative stress in cultured brain 
endothelial cells.  Overall, these results suggest that targeted PEG-HCCs are potential 
therapeutics for the cerebrovascular dysfunction from mTBI and the results open 
additional possibilities for targeting a variety of pathological processes.   
Because of the deleterious effects of loss of cerebrovascular responsiveness, even 
in mild injuries, a therapy that mitigates oxidative injury to endothelial cells should hold 
promise for the improvement of outcome following mTBI.  Furthermore, because there is 
a major burst of superoxide radical at the time of resuscitation following TBI and 
hemorrhagic hypotension,7 treatment at the time of resuscitation may provide a clinically 
realistic time point that can address at least one pathological event in the care of the TBI 
patient.  Our previous work also showed that the enzymatic antioxidant, PEG-SOD, had 
only transient and minimal effect in an in vivo model of experimental TBI complicated by 
hypotension and resuscitation,7 consistent with lack of clinical benefit, and we have 
preliminary results that PEG-superoxide dismutase was effective in this Antimycin A 
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assay only when administered at high doses prior to the toxcin, whereas post-treatment 
with PEG-HCCs was quite effective. The effectiveness remained in the targeted ps/PEG-
HCCs.  This characteristic may be a major advantage in considering the use of this agent 
for treating TBI. Indeed, our preliminary results indicate that PEG-HCCs are able to 
restore cerebral blood flow following resuscitation in an experimental TBI model56 when 
treated during resuscitation. A more fully defined time course, both in vitro and in vivo 
will be necessary to confirm the treatment time window and effect on outcome. 
We are encouraged that targeting the PEG-HCC using a p-selectin antibody 
demonstrated a more rapid binding to stressed b.End3 cells.  This characteristic may have 
advantages as a therapeutic agent with enhanced binding to molecules expressed at the 
site of injury and possibly reduce the total dose administered to the patient.  There are 
many potential such targets, but p-selectin appears particularly promising as there is some 
added therapeutic benefit in experimental TBI of the antibody itself57,58 perhaps 
providing added benefit in addition to the antioxidant ability of the PEG-HCCs. Further 
comparisons of these different therapeutic approaches will be pursued. 
 
2.4. Conclusions 
In summary, we have described a new class of antoxidant materials that were 
developed to specifically address the cerebrovascular dysfunction that follows TBI.  We 
have shown that PEG-HCC’s bound to a p-selectin antibody are rapidly targeted to 
stressed endothelial cells and are antioxidants capable of reducing oxidative stress-related 
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fluorescence even when administered after a mitochondrial toxin. It is possible that their 
effectiveness following injury may be due to the unique mechanism of annihilating 
radicals, rather than relying on downstream antioxidants that may be depleted in the toxic 
post-TBI environment.  These cumulative characteristics support further testing in TBI 
models particularly those that involve cerebrovascular dysfunction such as mild TBI and 
hypotension/resuscitation where loss of cerebral autoregulation and poor reperfusion 
cause brain injury far beyond that of the TBI alone.8   
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2.7. Experimental Contributions 
I prepared the PEG-HCCs, performed and analyzed the ORAC, ascorbate 
oxidation, and benzoate hydroxylation assays.  Jane Jarjour, Juhey Lee, and Aakash 
Jacob ran the replicates for the ascorbic and benzoate hydroxylation assays. Dr. Bitner 
and Dr. Fabian ran the cells experiments. Dr. Berlin helped with the data analysis.  
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Chapter 3 
                    Antioxidant Carbon 
Particles Improve Cerebrovascular 
Dysfunction Following Traumatic Brain 
Injury 
This chapter was entirely copied from the reference #1 of this section 
 
3.1. Introduction 
The neurovascular unit, composed of neuronal and non-neuronal cells such as 
vascular cells, comprise an integrated network responsible for important physiological 
functions in the brain including regulation of blood flow.2 The brain has a high metabolic 
demand that is met by maintenance of cerebral blood flow (CBF) even under conditions 
of altered systemic blood pressure, a process termed cerebral autoregulation.3  It is 
achieved by the ability of the brain vasculature to dilate in the face of low blood pressure 
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and constrict during increased blood pressure in order to maintain its perfusion within 
physiological range. Loss of autoregulaion can expose the brain to hypoperfusion during 
low blood pressure (hypotension) and to excess blood flow and potentially bleeding 
during high blood pressure (hypertension).  Dysfunction of the neurovascular unit is 
recognized as a major determinant of patient outcome after brain injury, and it has been 
hypothesized that therapies that do not address that dysfunction are unlikely to promote 
recovery.2 In the case of traumatic brain injury (TBI), damage to the neurovascular unit is 
manifested under conditions of abnormally low blood pressure, known as hypotension, 
by loss of cerebral autoregulation and poor restoration of blood flow even after treatment 
with fluids to increase blood pressure (resuscitation).4 Loss of autoregulation and poor 
reperfusion contribute to the clinical finding that TBI with a secondary insult of 
hypotension predicts poor outcome.5 This poor outcome is seen even when the brain 
injury is classified as mild TBI, more commonly known as a concussion. Elevated levels 
of reactive oxygen species (ROS) such as superoxide (SO)6,7 are found in the vasculature 
and have been shown to mediate loss of autoregulatory tone.  Along with spikes of ROS 
following trauma, continued damaging spikes in the level of ROS are observed upon 
subsequent blood reinfusion during resuscitation;8 hence, in an effort to stabilize the 
patient, furtherance of oxidative damage ensues.9,10 However, blood reinfusion also 
provides an opportunity to intervene at a clinically realistic time point.  
A variety of  functionalized carbon materials such as single-walled carbon 
nanotubes, multi-walled carbon nanotubes, graphene, fullerenes, and/or their derivatives 
have been studied for the treatment of many diseases, including cancer,11-13 arthritis,14-16  
inflammation,17 and neurodegenerative18-20 diseases. In this report we demonstrate that 
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poly(ethylene glycol)-functionalized hydrophilic carbon clusters (PEG-HCCs), which are 
nontoxic carbon particles, rapidly restore cerebral blood flow (CBF) in a 
TBI/hypotension/resuscitation rat model when administered during resuscitation.  
Remarkably, along with restoration of CBF, there is a concomitant normalization of both 
SO and the vasodilator, nitric oxide (NO), levels.  
There are currently no antioxidants, including PEG-superoxide dismutase (PEG-
SOD) and tirilizad, which have improved patient outcome following TBI.21 One reason 
for the lack of effectiveness could be due to the mechanism by which antioxidants trap 
radicals.  Many of these agents modify the radical and depend on the presence of 
additional detoxifying molecules, such as catalase or glutathione to regenerate the 
antioxidant.21 Unfortunately, in the toxic post-injury environment, these downstream 
molecules are depleted and cannot sufficiently detoxify the damaging radicals.  Other 
agents, such as Vitamin E, are insufficiently regenerated in the face of rising levels of 
oxidative radicals.22 While it is probably not possible to administer therapy in time to 
avert the initial instantaneous spike in ROS following TBI, it should be possible to 
include an antioxidant at the time of resuscitation and reperfusion to avert the subsequent 
waves of damaging ROS and their damaging cascades. Therefore, a useful clinical agent 
would need to act rapidly in vivo following the release of the ROS, have high capacity for 
radical annihilation where there is no need for complementary detoxifying molecules, and 
it should be effective at a clinically realistic time point such as during the resuscitation.   
Particle-based systems are an emerging class of antioxidants with potential 
advantages over currently available antioxidants23-32 due to the possibility that they can 
fully quench radicals without the need for assistance from other detoxifying molecules, as 
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in the case of superoxide dismutase, for example.32 HCCs are chemically cut carbon 
materials, 30- to 40-nm-long and 2- to 3-nm wide, possessing both graphitic and oxidized 
domains, the latter being the addend locations for PEGylation via amide linkages.34 PEG-
HCCs are in vitro antioxidants,35 and they can also be non-covalently loaded with 
hydrophobic drugs for in vivo delivery.36 PEG-HCCs have the hydrodynamic volume of a 
moderately sized protein; hence, they are diminutive. Dynamic light scattering (DLS) 
measurements indicate that they are 50 nm in size at neutral pH.34 Preliminary studies 
that used histological analysis of major organs along with hematology measurements 
demonstrated that the PEG-HCCs have no acute toxicity, and a biodistribution study 
indicated that they were primarily cleared through the kidneys with a blood half-life of 2 
to 3 h.34 Finally, PEG-HCCs are room-temperature stable for months, biocompatible with 
cultured brain endothelial cells (bEnd.3), and they can be targeted with monoclonal 
antibodies, such as P-selectin, to specific cellular locations on tissue of interest.35,36  
It is conjectured that PEG-HCCs’ graphitic structural domains cause them to be 
antioxidants by radical annihilation (Figure 3.1) rather than by radical transfer to a less 
reactive radical form as is required for most other antioxidants. Thus, PEG-HCCs can 
detoxify many radicals at each of their graphitic domains, as demonstrated by our 
previous finding that PEG-HCCs are potent antioxidants after generation of SO, one of 
the damaging ROS overproduced during TBI.35  It is thus possible that in vivo the PEG-
HCCs can annihilate toxic ROS during periods of trauma when other antioxidants are 
overwhelmed due to a lack of supporting detoxifying molecules. Hence, PEG-HCCs 
alone may function as effective antioxidants and have sufficient capacity for radical 
annihilation to be used therapeutically during periods of intense ROS generation. These 
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multifaceted properties suggest that the PEG-HCCs could be exciting constructs for 
clinical evaluation. 
 
 
 
Figure 3.1. The suggested radical annihilation mechanism at a graphitic domain of the 
carbon particle. Two additions of RO· result in the loss of two C–C pi-bonds and the 
formation of two new C–O sigma bonds and one new C–C pi bond, without any radical 
species remaining.  Only one regioisomer is shown, though many others can form by 
resonance of the conjugated radical.   
 
3.2. Experimental Procedures 
3.2.1. Preparation and Characterization of the PEG-HCCs 
 PEG-HCCs were prepared as previously described.34 These particles are soluble 
in water and PBS. Optical spectrum (Figure C1, Appendix C), thermogravimetric 
analysis (TGA, Figure C1-B), and X-ray photoelectron spectroscopy (XPS, Figure C1-C, 
Appendix C) measurements were consistent with the previously reported33 
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characterization of these materials. According to the TGA, the PEG-HCCs used in the 
current studies were 84% PEG by weight.    
3.2.2. DAF-2DA Staining in bEnd.3 Cells 
bEnd.3 cells (ATCC) were grown in Dulbecco's modified Eagle's medium (4 mM 
L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate and 4.5 g/L glucose, 90%; 
fetal bovine serum, 10% (Atlanta Biological) in an incubator set to 37 °C with 5% CO2. 
Aliquots of 60,000 cells in 0.5 mL were added directly onto sterile 25 mm round cover 
glasses inside 6 well plates.  The cells were allowed to attach for 15 min after which an 
additional 1.5 mL of media was added and then the cells were placed in an incubator and 
allowed to grow for 48 h.  PEG-HCCs were added to each well to obtain the following 
concentrations: 0 mg/L, 0.1 mg/L, 1 mg/L, 10 mg/L, 20 mg/L and 30 mg/L (triplicate).  
The cells were incubated for 1 h with the specific PEG-HCC concentrations after which 
DAF-2DA at a final concentration of 5 mM was added to each well and incubated for an 
additional 5 min.  The cells were then washed 3× with PBS and fixed with 4% 
paraformaldehyde for 15 min.  The cells were washed 3× with PBS and then the cover 
glasses were attached to glass slides and coverslipped. A Nikon eclipse 80i microscope 
set to FITC was used to capture ten 40X fields per slide. Five cells from each 40X field 
were analyzed using NIS Elements software.  An auto detect region of interest (ROI) 
function was used to select the cells and calculate their mean intensity and area. The 
intensity/area/exposure was calculated.  An ANOVA was performed using the means 
followed by post tests using the Bonferroni method. 
3.2.3. Internalization of the PEG-HCCs 
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Confocal microscopy showed that the PEG-HCCs were taken up by the 
endothelial cells (Figure C2 – Figure C4, Appendix C). Staining against the PEG for the 
mock (Figure C2-B, Appendix C) and PEG (Figure C2-E, Appendix C) treated cells 
showed similar low intensity signals, indicating that uptake was dependent on the 
presence of carbon particles but not the PEG. The experiment was set as follow:  bEnd.3 
cells (~50,000/well, passage less than 30 times) were grown on coverslips placed in 6-
well plates with 5 mL of complete media (high glucose Dulbecco's modified Eagle's 
medium (Gibco) formulated to contain 4 mM L-glutamine, 3.7 g/L sodium bicarbonate, 
4.5 g/L D-glucose, 1 mM sodium pyruvate, 90%; fetal bovine serum, 10%; 1x pen-strep). 
Cells were later treated with 5 mL of complete medium in a 1:1 mixture with water 
(Mock treatment), a solution of PEG in water, or a solution of PEG-HCCs in water. The 
final concentration of the PEG and PEG-HCCs in the treatment solution was 4 mg/L. 
Cells were incubated at 37 °C with 5% CO2 for 5.5 h. The cells were then washed with 
ice cold PBS, then a solution of glycine (50 mM)/NaCl (100 mM), followed again by ice 
cold PBS in order to remove the carbon particles that are weakly attached to the 
membrane. Cells were fixed with 4% paraformaldehyde, then cell membranes were 
stained with Wheat Germ Agglutinin 594 before being permeabilized with PBT (PBS 
containing 0.1% Triton X-100), blocked with 5% BSA in PBT, and immunostained with 
a primary antibody against PEG (Epitomics, PEG Rabbit Monoclonal Antibody, 
RabMAb® #: 2061-1) and an Alexa-633 conjugated secondary antibody, with DAPI used 
as a nuclear counterstain. Each set of images was taken with the same settings on a Zeiss 
LSM 510 META confocal microscope, and are shown at the same brightness/contrast 
levels.  
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3.2.4. Animal Experiments 
A TBI/hypotension/resuscitation rat model was chosen to simulate a typical case 
in the field: 50 min after controlled cortical impact TBI and loss of blood, lactacted 
Ringers solution was administered in an ambulance “prehospital” phase, then after further 
delay of 30 min, definitive “hospital” care consisted of therapy administration, 
oxygenation and blood infusion. The model is described as follows:  In Phase 1, Long 
Evans rats (250 to 300 g) underwent sham injury or mild cortical compression injury TBI 
(3 m/s, 2.5 mm deformation, Table C1) to one hemisphere of the brain. Sham animals 
underwent identical surgical preparation as the TBI group except they did not receive the 
cortical impact used to produce mild TBI. Both sham and mild TBI animals had 
hemorrhagic hypotension produced by controlled blood withdrawal to reach a mean 
arterial blood pressure (MAP) of 40 mm Hg in a decelerating protocol to mimic trauma 
blood loss. In order to simulate field resuscitation and ambulance transport (Phase 2), the 
rats received intravenous (i.v.) lactated Ringer’s solution for initial resuscitation.  Then 
hospital care (Phase 3) was simulated by administering a single dose of PEG-HCCs (2 
mg/kg) or a diluent vehicle, phosphate buffered saline (PBS), via a 5 min i.v. tail vein 
administration. This was followed by oxygenation and blood reinfusion. Beginning with 
Phase 4, there was extensive physiological monitoring included MAP, arterial blood 
gases, intracranial pressure and non-invasive spatial brain perfusion using laser Doppler 
flowmetry (LDF, Periscan).37   
 
3.3. Results and Discussion 
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First, by confocal microscopy studies, we confirmed that the PEG-HCCs are 
rapidly internalized by murine brain endothelial (b.End3) cells (Figure C2 – Figure C4, 
Appendix C). Brain endothelial cells were chosen because, as discussed, the vasculature 
is a major and potentially treatable injury in the TBI and secondary injury paradigm that 
results in loss of autoregulation.4,6 A series of in vitro studies showed that when oxidative 
stress was induced in b.End.3 cells38 by treatment with the mitochondrial toxin, 
antimycin A,23,26,35,39 the intracellular oxidative stress could be reduced in a dose-
dependent manner by treatment with PEG-HCCs. Antimycin A blocks electron flow 
through complex III of the mitochondrial electron transport chain that results in the 
formation of SO.39 The amount of oxidative radical expression was measured as a 
proportion of dihydroethidium (DHE) fluorescence.40 PEG-HCC treatment was effective 
even 10 min after toxin exposure, while neither PEG-SOD nor the small molecule 
antioxidant, phenyl-α-tert-butyl nitrone (PBN)8,41,42 was effective in the post-toxin-
treated cells.  The latter two traditional antioxidants were only effective pre-toxin 
exposure, and then only at a 10 to 30× higher dose (Figure 3.2A).  Furthermore, at higher 
doses of antimycin A where significant cell death could be induced, post-treatment with 
PEG-HCCs was able to restore cell viability to more than 65% of baseline.  Conversely, 
no protective effect from post-treatment with either PEG-SOD or PBN could be observed 
(Figure 3.2B). These studies underscore the efficacy of the PEG-HCCs to annihilate ROS 
that would otherwise have resulted in cell death; the poor performance of conventional 
antioxidants is also noted. 
Furthermore, it was found that PEG-HCCs are selective antioxidants as additional 
in vitro experiments in bEnd.3 cells indicated that the PEG-HCCs do not quench NO 
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sensitive fluorescence of diaminofluorescein diacetate (DAF-2DA)42 associated with 
spontaneous NO release from these cells (Figure C5 and Figure C6, Appendix C). This 
may be significant for eventual clinical efficacy since physiological levels of NO are 
essential for many processes, including blood vessel dilation and autoregulation.43 An 
effective antioxidant treatment for TBI must annihilate toxic species such as SO without 
impairing the normal levels and functions of NO. 
 
 
Figure 3.2. PEG-HCCs protect brain endothelial cells from oxidative stress when 
administered after an insult. (A) Intracellular ROS levels for b.End3 cells as determined 
by DHE staining and flow cytometry. The mean fluorescent intensity (MFI) of 10,000 
cells/group was normalized to the group not treated with antimycin A (AntA in graphs) or 
DHE. Phosphate buffered saline (PBS, black bar) or antioxidant treatments (blue, green, 
and red solid bars) were given after antimycin A. Some antioxidants were administered 
prior to antimycin A (striped bars). Additional controls are shown in Figure C6 
(Appendix C). * p-value < 0.05; ** p-value < 0.01; *** p-value < 0.001 compared to bar 
with arrow. Results are a mean of five separate experiments. (B) Cell survival relative to 
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control for b.End3 cells given different treatments. The cells were either cultured in the 
presence of PEG-HCCs, PEG-SOD or PBN alone (solid bars) or the cells were first 
treated with a dose of antimycin A titrated to kill 30% of the cells followed by treatment 
with PEG-HCCs, PEG-SOD or PBN (striped bars). Results are a mean of seven separate 
experiments. Error bars are s.e.m. ANOVA with Bonferroni post test was used to 
calculate statistics. * p-value <0.05.  
 
PEG-HCCs were next evaluated in vivo. The TBI model used here is intended to 
mimic the common clinical situation in which TBI is accompanied by a systemic injury 
resulting in hypotension (low blood pressure). There is minimal evidence of either 
behavioral or histological injury with either TBI or hypotension alone, but with the 
superimposition of hemorrhagic hypotension and subsequent resuscitation, there is 
marked expansion of lesion size and behavioral impairment (Figure C7, Appendix C).37 
Reperfusion CBF was reduced in proportion to the increase in injury, supporting the 
hypothesis that this is primarily a vasculature injury. The loss of autoregulation and poor 
reperfusion originating in the brain endothelium contribute to injury even in the setting of 
mild TBI. This highlights that while the blood-brain barrier becomes compromised 
following mild TBI44 potentially allowing access of agents such as PEG-HCCs to the 
brain itself, the major treatable injury in the TBI and secondary injury paradigm is to the 
brain vasculature manifested by loss of CBF and poor reperfusion.    
Using this TBI/hypotension/resuscitation rat model, treatment was chosen to 
simulate a typical case in the field: 50 min after controlled cortical impact TBI and loss of 
blood, lactacted Ringers solution was administered in an ambulance “prehospital” phase, 
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then after further delay of 30 min, definitive “hospital” care consisted of therapy 
administration, oxygenation and blood infusion. The model is outlined in the Injury 
Model Table 1 and described as follows:  In Phase 1, Long Evans rats (250 to 300 g) 
underwent sham injury or mild cortical compression injury TBI (3 m/s, 2.5 mm 
deformation, Table C1, Appendix C) to one hemisphere of the brain. Sham animals 
underwent identical surgical preparation as the TBI group except they did not receive the 
cortical impact used to produce mild TBI. Both sham and mild TBI animals had 
hemorrhagic hypotension produced by controlled blood withdrawal to reach a mean 
arterial blood pressure (MAP) of 40 mm Hg in a decelerating protocol to mimic trauma 
blood loss. In order to simulate field resuscitation and ambulance transport (Phase 2), the 
rats received intravenous (i.v.) lactated Ringer’s solution for initial resuscitation.  Then 
hospital care (Phase 3) was simulated by administering a single dose of PEG-HCCs (2 
mg/kg) or a diluent vehicle, phosphate buffered saline (PBS), via a 5 min i.v. tail vein 
administration. This was followed by oxygenation and blood reinfusion. Beginning with 
Phase 4, there was extensive physiological monitoring included MAP, arterial blood 
gases, intracranial pressure and non-invasive spatial brain perfusion using laser Doppler 
flowmetry (LDF, Periscan).37   
 
Table 3.1. Injury Model 
Phase 1 
Injury and 
hemorrhage 
Phase 2 
Prehospital 
ambulance 
Phase 3 
Definitive 
hospital 
Phase 4 
Test 
outcome 
82 
 
(50 min) (30 min) (30 min) (6 h) 
• Ventilate (air) 
• Mild TBI  
• Withdraw blood to 
MAP 40 mm Hg 
• Ventilate (air) 
• Initial resuscitation 
saline  MAP ≥ 50 
mm Hg 
 
• Give drug 
• Ventilate with 
100% oxygen 
• Reinfuse blood 
• Saline to MAP ≥ 
60 mm Hg 
• 0-6 h Monitor 
cerebral 
hemodynamics  
• 6 h Determine 
SO and NO 
levels 
 
Remarkably, PEG-HCCs restored cerebral perfusion and normalized the oxidative 
radical profile.  Rats received a single dose of PEG-HCCs (2 mg/kg) or PBS at the 
beginning of the blood resuscitation (Phase 3). CBF was measured for 6 h from the brain 
surface with LDF (Phases 3 and 4). Just before the 6 h mark, rats were injected with dyes 
for SO (DHE) and NO (DAF-2DA) detection, and perfusion fixed.42 Systemic injection 
of these dyes and a short circulation time was able to identify vascular expression of 
these radicals since the dyes are concentrated in the vasculature with less chance of 
diffusion into the brain parenchyma.42 LDF-relative CBF (rCBF) is shown in the series of 
Figures 3.3A-C.  Figure 3.3A illustrates changes in rCBF in the region of the traumatic 
injury. Hypotension following TBI significantly reduced rCBF.  In the vehicle-treated 
TBI group, rCBF was only partially restored by reinfusion of shed blood while rCBF 
returned rapidly to baseline levels following administration of the PEG-HCCs and blood. 
The duration of the PEG-HCC effect was from 2 to 3 h, at which time both groups 
showed a decline in rCBF; this duration of treatment effect is consistent with the 2 to 3 h 
blood half-life of PEG-HCCs34 and also consistent with the prolonged anesthesia time. 
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Figure 3.3B shows a qualitatively similar effect in the peri-traumatic region (region 
around the injury), with rCBF returning to baseline in the PEG-HCC-treated group, while 
remaining depressed in the vehicle-treated group. No effect on rCBF of either group in 
the contralateral cortex  (Figure 3.3C) indicates that the outcomes seen in the lesion and 
peri-lesional regions were not artifactual and were specific for injured areas.  Additional 
experiments in a model to simulate linear flow show that there was no effect of PEG-
HCCs on the LDF signal used to measure CBF, nor did the PEG-HCCs influence 
systemic blood pressure or physiological variables (Figure C8, Table C2, Appendix C). 
These results demonstrated that in a model of TBI/hypotension/resuscitation, the PEG-
HCCs rapidly restore the cerebral perfusion and that the PEG-HCCs were directly 
improving CBF in the injured area. 
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Figure 3.3. PEG-HCCs treatment rapidly improves CBF in the injured cortex in rats with 
TBI plus hypotension after a single dose and two sequential doses.  Laser Doppler was 
used to measure CBF given as a percent of the baseline (pre-injury) CBF. Relative CBF 
below 100 (dashed line) indicate low CBF. Relative CBF after a single drug dose (arrow) 
administered during the “hospital phase” in the (A) injured cortex (B) peri-lesional 
cortex, and (C) contralateral cortex; the effect of sequential dosing in a second set of rats 
treated with drug during the “hospital phase” and again 2 h later (arrows) are shown in 
(D) injured cortex (E) peri-lesional cortex, and (F) contralateral cortex.  Drugs (PEG-
HCC or PBS vehicle) were given where indicated. Time 0 min indicates when the TBI 
was performed. Phase 1 = TBI+hypotension; Phase 2 = saline during “ambulatory 
phase”; Phase 3 = vehicle or PEG-HCC treatment and blood reinfusion during “hospital 
phase”. Error bars are S.E.M. Repeated measures ANOVA with Bonferroni post test was 
used to calculate statistics. * p-value <0.05 and *** p-value <0.01 for vehicle (red) 
compared to PEG-HCCs (blue). Note that 100% of CBF is considered “normal”. 
Approximately 50% and 150% are considered low and high cerebral blood flow, 
respectively. 
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We next determined whether treatment was able to modify the hypothesized 
targets, SO while restoring NO.  The injection of PEG-HCC antioxidants significantly 
reduced SO levels in the vasculature (Figures 3.4A-C), underscoring that this is primarily 
a vasculature injury.  Concomitantly, treatment with PEG-HCCs completely restores 
vascular NO levels (Figures 3.4D-E).  This duality of modes in the resuscitative phase of 
treatment, specifically decreasing SO and normalizing NO, is highly unusual in such 
injury models. 
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Figure 3.4. Fluorescence after systemic injection of radical-sensitive dyes measured in 
the brain and vasculature following TBI.  DHE levels (proportional to SO and oxidative 
radicals) in the (A) brain parenchyma (cortex) and (B) blood vessels of sham (no TBI) 
surgery rats or rats with TBI + hypotension with vehicle or PEG-HCC treatment. The 
ipsilateral cortex (brain hemisphere with TBI) was normalized to the contralateral cortex. 
PEG-HCC treatment was able to reduce DHE staining (blue column) compared to vehicle 
treatment (red column), with a larger magnitude of effect seen in the blood vessels than 
the brain parenchyma, suggesting that the cerebrovascular is likely the site of major 
dysfunction in the TBI model. (C) Microscopy of DHE staining (red) in the injured 
cortex; scale bar = 200 μm showing the prominent fluorescence in vascular structures 
(long thin structures). DAF-2DA levels (indicative of NO levels) are shown in (D) for the 
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brain parenchyma (cortex) and (E) blood vessels of sham surgery rats or rats with TBI + 
hypotension with vehicle or PEG-HCCs treatment. (F) Microscopy of DAF-2DA staining 
(green) in the injured cortex. NO-related fluorescence was reduced following TBI and 
restored to levels comparable to the sham-treated animals. NO is important for 
vasodilation and increased CBF, therefore, increased DAF-2DA staining with PEG-HCC 
treatment correlates well with the improved CBF from Figure 3.3. Both DHE and DAF-
2DA fluorescence was normalized in each animal to the contralateral cortex to account 
for minor differences in dye administration and circulation times. For all data in this 
Figure, error bars are S.E.M. D'Agostino-Pearson normality test was used on data and no 
groups had a p-value <0.05. ANOVA with Bonferroni post test was used to calculate 
statistics. * p-value < 0.05; ** p-value < 0.01; *** p-value < 0.001. N=5-6 animals/group 
with 10 brain sections analyzed per animal. Scale bar = 200 μm. 
 
3.4 Conclusions 
Non-toxic PEG-HCCs are inherently active particle-based drugs that have 
efficacy at the critical neurovascular unit, restoring CBF after a mild TBI.  Since 
reduction in CBF following even mild TBI is a major cause of poor outcome, the results 
shown for restoring CBF while normalizing SO and NO levels primarily in the cerebral 
vasculature are suggestive of a treatment that could vastly improve the recovery and 
long-term neurological prognosis for traumatized patients, and it has implications for 
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other acute disorders such as stroke in which reperfusion-based ROS release is associated 
with extension and propagation of injury.8 
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I prepared, purified, and characterized the PEG-HCCs. Also, I worked with James 
Culver on the internalization of the nanoparticles experiments. Dr. Bitner and Leela 
Cherian performed in vitro and animals experiments.  
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Chapter 4 
                    Antibody-Targeted 
Nanovectors for the Treatment of 
Brain Cancers 
This chapter was entirely copied from the reference #1 of this section 
 
4.1. Introduction 
Glioblastoma multiforme (GBM) is the most common and aggressive malignant 
primary brain tumor in humans. GBM prognosis is poor, with a 14 month median 
survival time despite interventions.2 Nanovectors, nanoparticles capable of transporting 
and delivering drugs and bioactive molecules, are an emerging class of drug delivery 
platforms.3 Some nanovectors, such as hydrophilic carbon clusters (HCCs)4-6 and single-
walled carbon nanotubes,7 can be engineered to possess both hydrophobic and 
hydrophilic domains, combining high aqueous solubility with the ability to adsorb 
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hydrophobic compounds. Therefore nanovectors are an exciting avenue for drug delivery 
of such compounds without the need for covalent drug or covalent antibody attachment7,8 
and could be used to target glioma.8-12  
HCCs are heavily oxidized carbon nanoparticles that are 30 to 40 nm long and 
approximately 1 nm wide, and although water soluble, they must be further 
functionalized with poly(ethylene glycol) (PEG-5000 MW) to maintain their solubility in 
phosphate buffered saline (PBS), thereby rendering the PEG-HCCs nanovector system.  
Their synthesis and characterization has been described previously.4,5 PEG-HCCs have 
three properties that allow them to be used as nanovectors: extremely low biological 
toxicity with clearance mainly through the kidneys,4 hydrophobic domains of the PEG-
HCCs that can be non-covalently loaded with drugs,4,6 and an ability to strongly bind to 
IgG-type antibodies while the antibodies maintain the majority of their activity.5,6 Thus, 
drug-loaded PEG-HCCs combined with an IgG will bind to a chosen cell surface antigen 
and deliver a hydrophobic, lipophilic drug into cells that express the selected epitope. We 
use the nomenclature: EpitopeAB/Drug/PEG-HCCs to describe a particular hydrophilic 
carbon cluster antibody enhancement system (HADES) composed of an antibody, a drug, 
and the PEG-HCCs delivery platform. In this nomenclature, non-covalent sequestration is 
indicated with a slash, “/”, and covalent bonding with a dash, “-”.  In each case, the drug 
and the antibody are added, sequentially, to the PEG-HCCs by simple mixing, hence a 
facile “mix-and-treat” toolbox is afforded.5  
We have sequestered three potent hydrophobic chemotherapeutic agents onto the 
PEG-HCCs, chosen on the basis of theoretical synergistic effect. These include (a) SN-
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38, a topoisomerase I inhibitor, which arrests the cell cycle in the S and G2 phases,13 (b) 
Vinblastine (Vin), which causes microtubule detachment from spindle poles, arresting the 
cell cycle in the M phase at the mitotic spindle checkpoint,14 and (c) Docetaxel (Doc), 
which binds tubulin, preventing microtubule depolymerization and arresting the cell 
cycle in both the G2 and M phases, resulting in mitotic catastrophe.15 Of note, SN-38 is 
dramatically more potent than the pro-drug form, Irinotecan®, but SN-38 cannot be 
directly administered to patients due to its extremely low aqueous solubility.16  The use of 
the HADES system allows for the direct delivery of this active drug, and perhaps other 
pharmaceutics, whose solubility requires the use of  moieties that increase solubility, but 
limits drug efficacy. 
To treat GBM, we selected immunoglobulin G antibodies (IgGs) to cell surface 
epitopes that are overexpressed in glioma cells relative to other cell types. GFAPAB is an 
IgG-type antibody to the glial fibrillary acidic protein (GFAP), a protein present in 
reactive astrocytes and also highly expressed in the majority of GBM cells.17 The 
interleukin-13 receptor (Il-13R) is a cytokine receptor, binding interleukin-13, and has 
been found to be upregulated in a large range of cancers, including GBM.18 Normal, 
unreactive, astrocytes express low levels of GFAP19,20 and even lower levels of IL-13R.21 
The epidermal growth factor receptor (EGFR) is the cell-surface receptor for members of 
the EGF family of extracellular proteins. This receptor is overexpressed, in either full 
length or truncated form, in many cancers including GBMs.22 Surface epitope mapping 
was performed on primary glioma cell cultures and the binding of specific IgGs to 
GFAP:IL-13R:EGFR had ratios of 1.0:1.3:1.6, respectively (Appendix D, Figure D1A-
C).  
101 
 
We examined the effectiveness of the antibody-targeted, IgG/drug/PEG-HCCs in 
primary human glioma cultures and control cultures of normal human astrocytes (NHA) 
and human cortical neurons (HCN). As GBM generates blood–brain barrier defects, this 
antibody-guided drug delivery system might ultimately be used intravenously to actively 
target glioma cells.23 
 
4.2. Experimental Procedures 
4.2.1. HCCs Functionalization, Drug Loading and Antibody Binding 
  The HCCs, PEG-HCCs and Drug/PEG-HCCs were prepared as reported by Berlin 
et al.5 Drugs were dissolved in a minimal amount of methanol (for Vin and Doc) or THF 
(for SN-38) and added dropwise into a stirring aqueous solution of PEG-HCCs. After 
overnight sonication, the organic solvent was removed by rotary evaporating one-third of 
the original volume of solution, adding one-third volume of water, and carrying out the 
same protocol evaporation/addition of water two more times according to published 
protocols.4 Vin (LogP 4.8) was incorporated into PEG-HCCs with a mass ratio of 5:1; 
Doc (LogP 2.92) was incorporated into PEG-HCCs with a mass ratio of 1.7:1 and SN-38 
(LogP 1.87) was incorporated into PEG-HCCs with a mass ratio of 0.33:1. Three mouse 
monoclonal antibodies, IgGs with affinities to cancer cell surface epitopes GFAP (2A5), 
Il-13R (YY-23Z) and EGFR (528), were obtained from Santa Cruz Biotechnology (Santa 
Cruz, CA, USA). Prior to use, drug-loaded PEG-HCCs were vortexed for 15 min and 
then were co-incubated with IgG for 15 min before being diluted and added to cell media. 
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We used a mass ratio of PEG-HCCs:IgG of 4.1:1 throughout. Although heterogeneous, 
the average molecular mass of PEG-HCCs is ~920,000, which gives rise to a molar PEG-
HCCs:IgG ratio of 1:1.5. Assuming the binding distribution to be Poissonian, ~80% 
PEG-HCCs have one or more IgGs bound. Visualization of mouse IgG was performed by 
incubating Alexa Fluor 594 goat anti-mouse IgG (Molecular Probes), overnight. The 
levels of Alexa Fluor-IgG were calibrated using a 5 µm thick, gelatin tissue phantom, 
entrapping 150 µg mL-1/1 µM goat-IgG21.  
4.2.2. Cell Cultures  
Primary human glioblastoma or astrocytoma cells were prepared from tumors 
within 10 min of their excision. The tumors were broken up using a pipette and then 
grown in DMEM, 20% FBS, GlutaMax-I, sodium pyruvate and Pen/Strep, for 2 weeks. 
After this time, and in all presented data, the same media was used, except that sodium 
pyruvate was omitted. NHA were obtained from Lonza (Walkersville, MD, USA) and 
HCN from the American Type Culture Collection (ATCC Manassas, VA USA), and 
grown subject to their recommendations. NHA were grown in Astrocyte Cell Basal 
Medium supplemented with 3% FBS, Glutamine, Insulin, fhEGF, GA-1000 and Ascorbic 
acid. HCN using ATCC-formulated Dulbecco's Modified Eagle's Medium (Cat#30-2002) 
and supplemented with 10% FBS. GBM and NHA were grown to confluency in the 
appropriate media on Costar 96-well growth plates (Corning, NYC, NY, USA) and HCN 
were grown on 16-well Lab-Tek slide chambers (Nalge Nunc, Rochester, NY, USA). 
Cells were grown for 24 h in the presence/absence of all effectors, in a total volume of 
250 µL. 
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4.2.3. Assays  
The ability of PEG-HCCs to take up hydrophobic solutes compromises a large 
number of high throughput proliferation assays. We find that many common reporter 
chromophore/fluorophores partition into PEG-HCCs and then undergo altered 
absorbance/fluorescence properties.4,5 PEG-HCCs also interfere with peptide-bond 
chelated copper reduction of Folin-Ciocalteu reagent (phosphomolybdate/ 
phosphotungstate), making the Lowery protein assay unsuitable.  
4.2.4. Protein Measurement  
Cell proliferation studies with PEG-HCCs included four HCN controls: 100 µM 
CCCP (100% cell death), saline vehicle, PEG-HCCs and IgG/PEG-HCCs using 
monoclonal antibodies toward GFAP, IL-13R or EGFR; three HADES treatments where 
PEG-HCCs loaded with the drugs Vin, Doc, or SN-38 were added to HCN with or 
without antibodies; and a final triple pairing with or without antibodies. After 24 h the 
cells were washed with PBS, solubilized using 0.1% SDS and then the protein present in 
the well was measured using the Thermo Scientifics Micro Bicinchoninic acid (BCA) 
Assay Kit (Waltham, MA, USA) and the data displayed in Figure D2 (Appendix D).  
4.2.5. Cell Viability Measurements  
The measurements and quantification of DNA 3’OH and blunt ended breaks by 
use of the ddTUNEL and blunt ended ligation were performed as described in our recent 
publications.25,35 The biotinylated ddUTP and biotinylated blunt ended oligonucleotide 
probe was visualized using Texas Red labeled avidin. Cells were incubated with 500 nM 
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Mitotracker Red (Cat#M22425), 1 µM Hoechst 33258 (Cat#H1398) and 100 nM Dead 
Green (Cat#I10291), with reagents obtained from Molecular Probes (Eugene, OR, USA). 
The activity of Caspase-3 in fixed, 0.1% Triton permeabilized cells was measured using 
the Molecular Probes R110-EnzChek Assay Kit (Cat#E13184), incubating cells for 1 h at 
37 °C. Signals from Dead Green/R110 and from Mitotracker were calibrated against 
known concentrations of liquid FITC-gelatin and Texas Red-gelatin and then against 
FITC/Texas Red gelatin tissue phantoms 5 µm in thickness.25,29 
4.2.6. Viability Cut-Off  
Cells were counted at 4× magnification using a Nikon Eclipse TE2000-E 
fluorescent microscope equipped with a CoolSnap ES digital camera system (Roper 
Scientific) containing an CCD-1300-Y/HS 1392 × 1040 imaging array cooled by a Peltier 
device. Images were recorded using Nikon NIS-Elements software as JEP2000 files. 
Cells were deemed to be non-viable if they had Dead Green/Hoechst signals >5 times the 
level found in control cells and >4.2 times the level of ddTUNEL labeled DNA 3’OH 
ends in control cells. 
 
4.3. Results and Discussion 
In Figure 4.1A we demonstrate the ability of the HADES formulation 
GFAPAB/SN-38/PEG-HCCs, with each component concentration at 3.9 nM, 2 µM, and 
2.6 nM, respectively, to induce cell death in primary GBM cell cultures. Due to the fact 
that nanomaterials can often interfere with biological assays,24 three different 
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methodologies were used to measure cell viability. Total, viable, and dead gliomal cell 
numbers in confluent primary GBM cell cultures were measured using ddTUNEL (a 
quantitative assay for 3’OH DNA ends),25 Dead Green,26 and Hoechst stains.25 Cells were 
treated with GFAPAB/SN-38/PEG-HCCs or saline for 24 h. SN-38 induced cell death 
could be monitored by all three viability methodologies, but there was slight under 
reporting of total cell numbers using both ddTUNEL and Dead Green, with respect to 
Hoechst, due to the presence of overlapping cells.27 It is clear that the three 
methodologies are robust even in the presence of nM concentrations of PEG-HCCs. 
Figure 4.1A further shows that in the saline control viable cell numbers increased from 
the ≈30,000 inoculum to 52,000 cells mL-1 in 24 h, whereas incubation with 
GFAPAB/SN-38/PEG-HCCs, there was a fall in cell numbers to only 22,000 cells mL-1. 
Moreover, there was a three-fold increase in the number of dead cells following treatment 
with HADES. 
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Figure 4.1. Four measures of viability all show that HADES therapy kills GBM primary 
cultures. (A) The three cell viability measures; ddTUNEL (white bars), Dead Green (gray 
bars) and Hoechst staining (striped bars) all give similar live/dead numbers (averages are 
the black bars) in GBM cultures in the absence (controls, left) and presence (HADES, 
right) as GFAPAB/SN-38/PEG-HCCs with each component at the following 
concentrations: 3.9 nM, 2.6 nM, and 2 µM, respectively. Viable cell numbers fall to only 
44% of the control in HADES treated cells and the dead cell fraction rises from 5.5% to 
31%. (B) The average levels of living GBM cells (left), from ddTUNEL, Dead Green and 
Hoechst staining, show that the individual HADES components, PEG-HCCs, 
GFAPAB/PEG-HCCs, and SN-38/PEG-HCCs are non-toxic, whereas HADES treatment, 
in the form of GFAPAB/SN-38/PEG-HCCs, causes significant cell death. Additionally, 
changes in cell protein mass, using the BCA method (right panel), correlate with viable 
C 
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cell numbers determined using viability stains in fixed cells, using the lethal uncoupling 
agent CCCP to establish the minimum cellular protein levels. (C) Comparison of SN-38 
toxicity when presented to GBM in solution or as HADES. SN-38 is insoluble in water, 
so it had to be delivered in ethanol and was compared to an ethanol control. Thus, 
changes in protein mass after 24 h treatment with SN-38/PEG-HCCs (white bars) and 
SN-38 (black bars) were compared to saline or ethanol only controls, respectively. SN-
38/PEG-HCCs are not toxic up to 20 µM SN-38, whereas aqueous SN-38 has an LD50 of 
~ 8 µM. In all figures n = 8 wells and the error bars are equal to the SD. 
 
Figure 4.1B (left panel) shows that the individual components of HADES 
treatment, PEG-HCCs (2.6 nM), GFAPAB (3.9 nM) and SN-38 (2 µM), are not toxic 
towards cell when added individually. Only when the three components: targeting 
antibody, chemotherapeutic and nanovector are all combined is there an increase in cell 
death. Addition of the three individual HADES components to glioblastoma cells results 
in no statistically significant difference in cell viability. Remarkably, we find that PEG-
HCCs alone are not toxic towards glioma, astrocytes or neurons at concentrations more 
than three orders of magnitude greater than those used in all the experiments related to 
Figure 4.1 (Appendix D, Figure D3). This corresponds with previous reports showing 
that PEG-HCCs are not toxic to mammalian cell cultures or in mice.4-6  
Cell counting assays are time consuming; in order to validate a high data 
throughput assay, we compared the changes in cell numbers obtained from viability 
studies with the use of the bicinchoninic acid (BCA) assay of protein levels (Figure 
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4.1B). The maximum and minimum cellular protein levels were establish using a saline 
negative control (100%) and carbonyl cyanide chlorophenyl hydrazone (CCCP) positive 
control (0%). Incubation of GBM for 24 h with CCCP (100 µM) induces cell death by 
mitochondrial uncoupling and allows the background matrix protein levels to be 
determined. Cellular protein levels following HADES treatment fell to 46% of the saline 
control level, mirroring the 44% levels of living cells determined using viability 
methodologies. 
The impact of sequestering SN-38 on the hydrophobic core of the PEG-HCCs was 
evaluated by comparing the changes in cellular protein of GBM following 24 h 
incubation with SN-38/PEG-HCCs or SN-38 alone (Figure 4.1C).  As mentioned 
previously, SN-38 is extremely insoluble in water;16 for this reason, in experiments using 
bulk phase drug we added either 5 µL of ethanol or ethanol containing SN-38 to each 250 
µL well volume. The two controls, ethanol and saline, had no significant change in 
cellular protein relative to one another. We found that aqueous SN-38 has an LD50 of 
approximately 8 µM toward primary GBM, within the 5-10 µM range reported by others 
using immortalized human glioblastoma cell cultures.28 Interestingly, no toxicity is 
observed when SN-38 is presented to the cells in the form of SN-38/PEG-HCCs, even at 
concentrations as high as 20 µM. This indicates that the SN-38/PEG-HCCs, without 
antibody targeting, cannot deliver the drug to the GBM cells at any significant rate. 
In Figure 4.2 we show that HADES treatment is toxic towards a variety of human 
glial cell carcinomas and that the system is flexible with respect to the loaded 
chemotherapeutic. In Figure 4.2A we show the titration of three different primary GBM 
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cultures, and one primary anaplastic astrocytoma (solid line), with GFAPAB/SN-38/PEG-
HCCs. The three GBM cultures, which have a doubling time of 28 to 34 h, have a 
common dose response with a LD50 of 1.5 to 2 µM SN-38, delivered in the form of 
HADES. In the slower growing anaplastic astrocytoma, which has a doubling time of 48 
to 52 h, the LD50 is elevated to ~3.75 µM SN-38. In Figure 4.2B we show the dose 
response of GBM towards three different chemotherapeutics, SN-38, Vin, and Doc which 
were loaded into PEG-HCCs and guided to the cell membrane using EGFRAB. The 
highest concentration of GFAPAB used on the confluent cells was 10 nM. In control 
experiments, we incubated for 1 h with GFAPAB/SN-38/PEG-HCCs, with each 
component concentration at 10 nM, 5 µM, and 6.5 nM, respectively. Then, fixed cells 
were stained using a labeled goat anti-mouse secondary antibody. Results indicated 86% 
saturation of the total surface GFAP epitopes, indicating that only 14% of the surface 
epitope is not bound to GFAPAB/SN-38/PEG-HCCs (Appendix D, Figure D1D). Using 
this nanovector delivery system, the LD50 for both SN-38 and Vin is ~1.5 µM while for 
Doc it is ~3 µM.  
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Figure 4.2. HADES therapy is highly versatile, having broad antibody/drug specificity 
and it is lethal toward a range of GBM. (A) The dose response curve of three different 
GBMs (dashed lines) and one anaplastic astrocytoma (solid line) toward anti-
GFAPAB/SN-38/PEG-HCCs, measured at 24 h. (B) HADES treatment using three 
hydrophobic drugs: Vin (□), Doc (○) and SN-38 (◊) were presented to GBM for 24 h 
within PEG-HCCs, targeted to the tumor antigen, EGFR, by an IgG. (C) Astrocytes are 
insensitive to HADES and the individual HADES components, as shown by protein 
measurement following 24 h incubation. Control (white bar on left), incubation of NHA 
with EGFRAB and EGFRAB/PEG-HCCs (next two black bars) and then with EGFRAB in 
the absence (gray bars) and presence (black bars) of PEG-HCCs ± drug (5µM) causes no 
change in protein mass.  
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In Figure 4.2C we show the effects of 5µM Drug/PEG-HCCs ± EGFRAB 
treatment on normal human astrocyte total protein levels, a treatment that caused >85% 
cell death in glioma. Neither PEG-HCCs nor EGFRAB/PEG-HCCs cause cell death. 
Extraordinarily, astrocytic mass was unaffected by the three EGFRAB/drug/PEG-HCCs 
combinations, each of which was overwhelmingly lethal to GBMs.  
Clinically, the use of combined therapy in cancer treatment is an attempt to evade 
the heterogeneous response that a cancer cell population has toward different 
chemotherapeutics and the ability of cancer cells to rapidly acquire drug resistance. As 
SN-38, Vin, and Doc all have different pharmacologic targets, we postulated that the 
three drugs might be able to potentiate each other’s anti-cancer properties. We incubated 
GBM, and also control NHA and HCN, with low levels of the three drugs in HADES 
form: consisting of three individual HADES formulations and an additional triple 
combination therapy where the three HADES individuals were combined (Figure 4.3). 
The low drug levels chosen, 0.5 µM, allowed enough damaged and dying cells to remain 
at the end of a 24 h incubation to be characterized using specific probes of DNA damage, 
mitochondria dysfunction, loss of plasma membrane potential and of the initiation of 
apoptotic, proteolytic, cascades.  
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Figure 4.3. Effects of Vin, Doc and SN-38 HADES individual or triple therapy on GBM 
measured using six different death markers; all drugs at a final concentration of 0.5 µM. 
The upper row shows 3’OH DNA ends, Dead Green and Hoechst DNA staining, the 
middle row shows mitochondrial membrane potential and the bottom row shows blunt 
ended, lethal, DNA breaks25,29 and Caspase-3 activity. All of the figures are at 20× 
magnification and the side bars show the calibration scale for each fluorophore.25,29 
 
The upper panel of Figure 4.3 shows the effects of the individual drugs and triple 
therapy on the viability of glioma primary cultured GBM cells, demonstrated by 
ddTUNEL (red)25 and Dead Green and Hoechst (blue). It is evident that both Vin and 
Doc have devastating impacts on GBM. Microscopic examination shows evidence of 
mitotic catastrophe and of the presence of gear-wheel-shaped nuclei, typical of the 
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microtubule disrupting actions of Vin30 and Doc.15,31 The center panel of Figure 4.3 
shows the loss of mitochondrial membrane potential with all four HADES regimes. Vin 
has been shown to alter the distribution of mitochondria throughout cells and to cause 
mitochondrial ‘clumping’32 and this type of mitochondrial flocculation is clearly evident 
in GBM. We also observe changes in mitochondrial morphology and cytosolic 
distribution in GBM treated with EGFRAB/Doc/PEG-HCCs that are very similar to those 
observed in prostate cancer cells treated with Taxels.31  
The lowest panels of Figure 4.3 show the levels of blunt ended DNA breaks25,29 
and Caspase-3 activity. All three individual HADES therapies cause increases in these 
lethal DNA breaks and in apoptotic, Caspase-3 activity.31 EGFRAB/Doc/PEG-HCCs in 
particular increases Caspase-3 activation, especially in the condensed cells, in which 
gear-wheel shaped nucleus predominate. In Figure D4A-C (Appendix D), we show the 
death labeling of two more primary GBMs and that of an anaplastic astrocytomoa, under 
conditions identical to that of Figure 4.3. In addition in Figure D4D-E (Appendix D), we 
show the effects of the same therapies on cultures of NHA and HCN. In stark contrast to 
the effects of HADES on the GBM, the effects on astrocytes and neurons are far more 
modest. Compared to control, for the four treatment groups, there is a doubling in the 
levels of ddTUNEL positive DNA 3’OH ends in NHA but no great increase in cell death. 
In Figure D4E (Appendix D), it is noteworthy that we observe no changes in nuclear 
structure of the treated neurons, even though neurons are very vulnerable towards 
microtubule disruption drugs like Doc31 and Vin (Figure D4F, Appendix D).34 
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Figure 4.4 shows the extent of cell viability and death, for GBM, NHA and HCN, 
using Hoechst staining. Figure 4.4A shows the levels of live and dead GBM cells 
following individual HADES treatments and the triple therapy. The two microtubule 
targeting chemotherapeutics are much more effective than the Topoisomerase-I inhibitor, 
SN-38. Treatment with Il-13RAB/SN-38/PEG-HCCs, GFAPAB/Vin/PEG-HCCs or 
EGFRAB/Doc/PEG-HCCs all produced a statistically significant, p < 0.01, drop in living 
cell numbers and an increase in dead cell percentages. There is a statistically significant, 
p < 0.01, synergistic effect caused by triple therapy, with respect to the individuals, on 
the level of cell death. 
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Figure 4.4. HADES triple therapy is not overly toxic towards astrocytes and neurons, but 
is highly toxic toward GBM. The living and dead cell numbers resulting from HADES 
treatment using 0.5 µM  drug (Vin, Doc and SN-38) targeted with monoclonal antibodies 
to GBM surface antigens (Il-13R, EGFR and GFAP), (A) as IgG/drug/PEG-HCCs in 
cultures of GBM, (B) astrocytes and (C) neurons. Black bars are % control living cells, 
white bars are % dead cells. (GBM: n = 8 wells; NHA: n = 8 wells; HCN: n = 4 wells; 
error bars SD in all cases). 
 
With respect to NHA and HCN, HADES treatment did not result in statistically 
significant changes in cell viability. However, in the case of HCN, only four wells were 
used for each treatment. Therefore, the number is too low to make accurate statistical 
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assertions. We therefore measured the changes in HCN protein levels in controls and 
following HADES treatment [as we had done with NHA (Figure 4.2C)], and we present 
this data in Figure D4 (Appendix D). The BCA assay shows that individual HADES 
therapies do not kill neurons, to any statistically significant degree, when using protein as 
a measure of cellular mass. However, combining the three drug-loaded PEG-HCCs, in 
the absence or presence of antibodies, does cause a statistically significant, p<0.05, 5% 
drop in cell protein levels. In spite of this increase in the killing of neurons, use of a 
multipronged therapy often has utility in treatment due to its potential ability to avoid the 
development of drug resistance.   
 
4.4 Conclusions 
In summary, we are able to target drug-loaded PEG-HCCs to the surface epitopes 
of cells, using specific antibodies. EGFR,35 IL-13R36 and GFAP37 are not present in 
human cortical neurons, but are found in high levels in GBM.35-37 Single or triple therapy 
is capable of killing gliomas with extreme lethality, while at the same time causing little 
or no ill-effects towards either astrocytes or neurons. The simplicity of the preparation 
where the PEG-HCCs, drug, and antibody are simply mixed together, coupled with the 
lethality of these combinations toward extremely aggressive cancers, provides 
encouragement for the continued testing of HADES. 
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4.7. Experimental Contributions 
I synthesized and purified the PEG-HCCs. Also, I prepared several Drug/PEG-
HCCs formulations in which the drug concentration and/or the nanoparticles 
concentration was varied in order to determine the most stable proportion of both 
components. Martyn Sharpe ran the cells studies.  
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Chapter 5 
                    Improved Synthesis of 
Graphene Oxide  
This chapter was entirely copied from the reference #1 of this section 
 
5.1. Introduction 
Graphene has enjoyed significant recent attention.2 Graphene is a single atomic 
layer of sp2 carbon atoms. Few- and single-layer transferable graphene nanosheets were 
first obtained by mechanical exfoliation (“Scotch-tape” method) of bulk graphite3 and by 
epitaxial chemical vapor deposition.4 Although those routes might be preferred for 
precise device assembly, they can be less effective for large-scale manufacturing. 
Chemical means are a practical approach to bulk-scale graphene materials.5 The primary 
obstacle to achieving individual or few-layer graphene is overcoming the enormous 
interlayer van der Waals forces. To date, chemical efforts at graphite exfoliation have 
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been focused primarily on intercalation, chemical derivatization, thermal expansion, 
oxidation-reduction, the use of surfactants, or some combination thereof.6-14 
The most common approach to graphite exfoliation is the use of strong oxidizing 
agents to yield graphene oxide (GO), a non-conductive hydrophilic carbon material.15-
18Although the exact structure of GO is difficult to determine, it is clear that for GO the 
previously contiguous aromatic lattice of graphene is interrupted by epoxides, alcohols, 
ketone carbonyls and carboxylic groups.19-21 The disruption of the lattice is reflected in an 
increase in interlayer spacing from 0.335 nm for graphite to more than 0.625 nm for 
GO.22 Brodie first demonstrated the synthesis of GO in 1859 by adding a portion of 
potassium chlorate to a slurry of graphite in fuming nitric acid.23 In 1898 Staudenmaier 
improved on this protocol by using concentrated sulfuric acid as well as fuming nitric 
acid and adding the chlorate in multiple aliquots over the course of the reaction.  This 
small change in the procedure made the production of highly oxidized GO in a single 
reaction vessel significantly more practical.24 In 1958, Hummers reported the method 
most commonly used today: the graphite is oxidized by treatment with KMnO4 and 
NaNO3 in concentrated H2SO4.16 It should be noted that all three of these procedures 
involve the generation of the toxic gas(es) NO2, N2O4, and/or ClO2; the latter also being 
explosive.  
The most common source of graphite used for chemical reactions, including its 
oxidation, is flake graphite, which is a naturally occurring mineral that is purified to 
remove heteroatomic contamination.25 GO prepared from flake graphite can be readily 
dispersed in water and has been used on a large scale for preparing large graphitic films, 
as a binder for carbon products and as a component of the cathode of lithium batteries.26-
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29 Moreover, the hydrophilicity of GO allows it to be uniformly deposited onto substrates 
in the form of thin films, which is necessary for applications in electronics.30 It is also 
often essential that the GO can be transformed back into a conductive graphitic material, 
and indeed, either in thin films or in bulk, partial restoration of the graphitic structure can 
be accomplished by chemical reduction13,30-32 to chemically converted graphene (CCG).  
However, the graphitic structure (with its desired properties) is not fully restored using 
these conditions, and significant defects are introduced.33 
Recently, we reported the scaleable preparation of graphene oxide nanoribbons 
(GONRs) from multi-walled carbon nanotubes by treatment with KMnO4 and 
concentrated H2SO431 and the discovery that the addition of phosphoric acid (H3PO4) to 
this reaction produced GONRs with more intact graphitic basal planes.34 Reduction of 
these second-generation GONRs produced ribbons that were comparable in conductivity 
to those prepared by reduction of the first generation GONRs. We hypothesized that this 
oxidation procedure (KMnO4 and a 9:1 mixture of concentrated H2SO4:H3PO4, called the 
“improved method” for clarity of discussion in this paper) could be used to prepare 
improved GO (IGO) with fewer defects in the basal plane as compared to GO prepared 
by the Hummers’ method. The IGO synthesis was evaluated in comparison to Hummers’ 
method or Hummers’ method with additional KMnO4.  For clarity, we have named the 
GO produced by these methods: IGO, HGO and HGO+, respectively. The improved 
method provides a greater amount of hydrophilic oxidized graphite material relative to 
the other two procedures. Moreover, even though IGO is as oxidized as HGO+ and both 
are more oxidized than HGO, IGO has a more regular structure with a greater amount of 
basal plane framework retained.  This is reflected in the fact that when all three GOs are 
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reduced with hydrazine hydrate, the CCG produced from IGO (CCIG) showed an 
equivalent level of conductivity with respect to the material produced from the other two 
methods (CCHG, CCHG+).  The advantages of the improved method, with its simpler 
protocol, higher yield, no toxic gas evolution during preparation and equivalent 
conductivity upon reduction, make it an attractive material for preparation on a large-
scale.  It may also show improved performance in materials applications, such as in 
membranes, TEM grids or temperature-sensitive device fabrication.  
 
5.2. Experimental Procedures 
Graphite flakes (Sigma-Aldrich, cat # 332461, ~150 µm flakes) were oxidized 
using three different procedures: improved method, Hummers’ method and Hummers’ 
method with additional KMnO4.  
For the improved method a 9:1 mixture of conc H2SO4:H3PO4 (360:40 mL) was 
added to a mixture of graphite flakes (3.0 g, 1 wt equiv) and KMnO4 (18.0 g, 6 wt equiv), 
producing a slight exotherm to 35-40 °C.  The reaction was then heated to 50 °C and 
stirred for 12 h.  The reaction was cooled to rt and poured onto ice (~400 mL) with 30% 
H2O2 (3 mL).  For work up, the mixture was sifted through a metal U.S Standard testing 
sieve (W.S Tyler, 300 μm) and then filtered through polyester fiber (Carpenter Co.)  The 
filtrate was centrifuged (4000 rpm for 4 h) and the supernatant was decanted away.  The 
remaining solid material was then washed in succession with 200 mL of water, 200 mL 
of 30% HCl, and 200 mL of ethanol (2×); for each wash the mixture was sifted through 
the U.S Standard testing sieve, and then filtered through polyester fiber with the filtrate 
being centrifuged (4000 rpm for 4 h) and the supernatant decanted away.  The material 
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remaining after this extended, multiple-wash process was coagulated with 200 mL of 
ether, and the resulting suspension was filtered over a PTFE membrane with a 0.45 μm 
pore size. The solid obtained on the filter was vacuum dried overnight at room 
temperature, obtaining 5.8 g of product.  
For Hummers’ method, concentrated H2SO4 (69 mL) was added to a mixture of 
graphite flakes (3.0 g, 1 wt equiv) and NaNO3 (1.5 g, 0.5 wt equiv), and the mixture was 
cooled to 0 °C. KMnO4 (9.0 g, 3 wt equiv) was added slowly in portions to keep the 
reaction temperature below 20 °C.  The reaction was warmed to 35 °C and stirred for 30 
min, at which time water (138 mL) was added slowly, producing a large exotherm to 98 
°C.  External heating was introduced to maintain the reaction temperature at 98 °C for 15 
min, then the heat was removed and the reaction was cooled using a water bath for 10 
min.  Additional water (420 mL) and 30% H2O2 (3 mL) were added, producing another 
exotherm.  After air cooling, the mixture was purified as described for the IGO above 
(sifting, filtration, multiple washings, centrifugations and decanting, vacuum drying) to 
give 1.2 g of solid. 
The third method makes use of the Hummers’ reagents with additional KMnO4.  
We call this method Hummers’ method+ and its product HGO+.  Concentrated H2SO4 
(69 mL) was added to a mixture of graphite flakes (3.0 g, 1 wt equiv) and NaNO3 (1.5 g, 
0.5 wt equiv), and the mixture was cooled using an ice bath to 0 °C. KMnO4 (9.0 g, 3 wt 
equiv) was added slowly in portions to keep the reaction temperature below 20 °C.  The 
reaction was warmed to 35 °C and stirred for 7 h.  Additional KMnO4 (9.0 g, 3 wt equiv) 
was added in one portion, and the reaction was stirred for 12 h at 35 °C. The reaction 
mixture was cooled to room temperature and poured onto ice (~400 mL) with 30% H2O2 
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(3 mL).  The mixture was then purified following the previous protocol of sifting, 
filtering, centrifugation, decanting with multiple washes followed by a final vacuum 
drying to give 4.2 g of solid product. 
 
5.3. Results and Discussion 
The increased efficiency of the IGO method as compared to the HGO and HGO+ 
methods was apparent after the first purification step for each method.  The hydrophilic 
carbon material produced during the reaction passed through the sieve while the under-
oxidized hydrophobic carbon material was retained on the sieve due to its particle size 
and low water solubility.  Significantly less under-oxidized material was generated in the 
production of IGO (0.7 g) compared to HGO (6.7 g) or HGO+ (3.9 g). Note that these 
weights correspond to the under-oxidized graphene and any water that was retained after 
drying overnight in vacuum; the HGO and HGO+ had a wet appearance (Figure 5.1). 
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Figure 5.1. Representation of the procedures followed starting with graphite flakes (GF). 
Under-oxidized hydrophobic carbon material recovered during the purification of IGO, 
HGO, and HGO+.  The increased efficiency of the IGO method is indicated by the very 
small amount of under-oxidized material produced. 
 
Following purification, the hydrophilic materials obtained (IGO, HGO, HGO+) 
were characterized.  Raman and infrared spectroscopy indicated that all three materials 
were similar. Raman spectra show D peaks ~ 1590 cm-1 and G peaks ~ 1350 cm-1, 
confirming the lattice distortions (Figure 5.2A). Also, FTIR-ATR spectra (Figure 5.2B) 
were recorded and the following functional groups were identified in all samples: O-H 
stretching vibrations (3420 cm-1), C=O stretching vibration (1720-1740 cm-1), C=C from 
unoxidized sp2-CC bonds (1590-1620 cm-1) and C-O vibrations (1250 cm-1).  
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 Figure 5.2. (A) Raman spectra recorded using 514 nm laser excitation and (B) FTIR-
ATR spectra of HGO+, HGO, and IGO. 
Atomic force microscopy (AFM) images (Figure 5.3) also indicated that the three 
materials were similar, as the thickness of the IGO, HGO+, and HGO layers were all ~ 
1.1 nm.  
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Figure 5.3.  Tapping mode AFM topographic images and height profiles of a single layer 
of (A) HGO+, (B) HGO, and (C) IGO.  
A variety of techniques indicated that the order of overall oxidation is HGO < 
HGO+ < IGO.  Thermogravimetric analysis (TGA) of the materials (Figure 5.4) showed 
major weight losses between 150-300 ºC, which corresponds to CO, CO2, and steam 
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release11 from the most labile functional groups. Between 400-950 ºC, a slower mass loss 
was observed and can be attributed to the removal of more stable oxygen 
functionalities.35 By TGA, HGO+ had the smallest weight loss while HGO and IGO had 
similar weight losses. 
 
Figure 5.4. TGA plots of HGO+, HGO, and IGO.   
 
Solid state 13C NMR (Figure 5.5) suggests that the order of overall oxidation is 
HGO < HGO+ < IGO.  The signals can be assigned as described previously:11,36,37 ketone 
carbonyls  near 190 ppm; ester and lactol carbonyls near 164 ppm, graphitic sp2 carbons 
near 131 ppm, lactols O-C(sp3)-O near 101 ppm, and alcohols at about 70 ppm with an 
upfield intense signal from epoxides near 61 ppm. The simplest measure of oxidation is 
the ratio between the alcohol/epoxide signal and graphitic sp2 carbon signal.  This ratio is 
greatest for IGO and least for HGO.  It is also noteworthy that IGO appears to have more 
epoxide functionalities than either of the other GOs. 
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 Figure 5.5.  50.3 MHz 13C NMR spectra obtained of HGO, HGO+ and IGO [12 kHz 
magic angle spinning (MAS), a 90° 13C pulse, 41-ms FID, and 20-s relaxation delay]. 
Integration areas are shown under each peak. 
 
The X-ray diffraction (XRD) spectra (Figure 5.6) support the same order of 
overall oxidation. For XRD, the interlayer spacing of the materials is proportional to the 
degree of oxidation. The spacings are 9.5 Å, 9.0 Å, and 8.0 Å for IGO, HGO+ and HGO, 
respectively. Also, the HGO spectrum had a peak at 3.7 Å, indicating traces of starting 
material (graphite flakes) were present in the sample.  
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Figure 5.6. XRD spectra of HGO, HGO+ and IGO (1.54059 Å Cu/K-alpha 1 as 
wavelength). 
 
The X-ray photoelectron spectroscopy (XPS) spectra of the samples both support 
the conclusion that IGO is the most oxidized material and suggest that the IGO has a 
more organized structure than the other two materials. To determine the relative levels of 
oxidation, the C/O ratio was not used; it is unreliable because it is so difficult to fully 
dehydrate a GO sample.38  Instead, the C1s spectra were compared by deconvoluting 
(Multipack software, version 7.0) each spectrum into four peaks that correspond to the 
following functional groups: carbon sp2 (C=C, 284.8 eV), epoxy/hydroxyls (C-O, 286.2 
eV), carbonyl (C=O, 287.8 eV) and carboxylates  (O-C=O, 289.0 eV).10 All percentages 
of the oxidized materials were combined such that IGO had 69% oxidized carbon and 
31% graphitic carbon; HGO+ had 63% and 37%;  HGO contained 61% and 39% of the 
oxidized carbon and graphitic carbon, respectively. The C1s XPS spectra were then 
normalized with respect to the C=C peak (Figure 5.7). The degree of oxidation for each 
sample is similar to the amount indicated by 13C NMR. IGO is the most oxidized 
material, HGO+ is slightly (~10%) less oxidized and HGO is the least oxidized.  
Moreover, the apparent peak at ~286 eV, corresponding to the oxidized carbons for IGO, 
is sharper than the same peak for HGO+.  This suggests that for similar levels of overall 
oxidation, the IGO has a more regular structure than that of HGO+.39 
139 
 
 
Figure 5.7.  The C1s XPS spectra of HGO+, HGO, and IGO normalized with respect to 
the C=C peak. 
 
Transmission electron microscopy (TEM) images of the three samples support the 
assertion that IGO has a more regular structure than either HGO+ or HGO (Figure 5.8). 
All three procedures produce large flakes of GO that are a few layers thick; however, the 
diffraction patterns indicate differences in crystallinity.  HGO is modestly crystalline, but 
when the more highly oxidized HGO+ is analyzed, an amorphous structure is indicated 
by the diffuse diffraction pattern.30,40 In comparison, the IGO is highly oxidized but has 
the sharpest diffraction pattern of all three samples, again suggesting that IGO has a more 
regular carbon framework than HGO or HGO+. 
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Figure 5.8. TEM images of (A) HGO+, (C) HGO, (E) IGO and their diffraction patterns 
(B), (D), and (F) respectively. Insets are the selected area electron diffraction (SAED) 
patterns corresponded to the graphene films in the TEM images. TEM grids with lacey 
carbon support films (Ted Pella, Inc.) were used to prepare the samples. 
 
The UV/Vis spectra of the three materials suggest that the more ordered structure 
of IGO is due to greater retention of carbon rings in the basal planes. The three spectra 
were recorded for an equal concentration of each material (Figure 5.9).  The degree of 
remaining conjugation can be determined by the λmax of each UV/Vis spectrum. The 
more π→π* transitions (conjugation), the less energy needs to be used for the electronic 
transition, which results in a higher λmax.   IGO, HGO+ and HGO all have a very similar 
λmax, which is in the 227-231 nm range as previously reported for GO.13,41 Also, for all 
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three materials, a similar shoulder around ~300 nm is observed and can be attributed to n- 
π* transitions of the carbonyl groups.  This suggests that the materials are grossly similar 
in structure, as the Raman, IR and AFM data indicated.  However, IGO has a larger 
extinction coefficient than those of HGO+ or HGO, suggesting that for an equal amount 
of each sample, the IGO has more aromatic rings or isolated aromatic domains retained.  
The λmax data indicates that these aromatic rings are not in extended conjugation, but the 
overall absorption indicates that IGO has more aromatic rings retained.  
  
Figure 5.9. UV/vis spectra recorded in aqueous solutions at 0.05 mg/mL of HGO+, 
HGO, and IGO.  
 
  Bulk samples of the oxidized materials were reduced using hydrazine hydrate 
and then annealed at 300 °C and at 900 °C in Ar/H2.  In general, for the hydrazine 
reduction, 100 mg of the IGO, HGO or HGO+ material was dispersed in 100 mL of DI 
water, stirred for 30 min and then 1.00 mL of hydrazine hydrate was added. The mixtures 
were heated at 95 ºC using a water bath for 45 min; a black solid precipitated from the 
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reaction mixture.  Products were isolated by filtration (PTFE 20 µm pore size) and 
washed with DI water (50 mL 3×) and methanol (20 mL 3×), producing 54 mg, 57 mg, 
and 76 mg of the reduced chemically converted IGO (CCIG),  chemically converted 
HGO+ (CCHG+) and chemically converted HGO (CCHG), respectively. After reduction, 
no signal from oxidized carbons could be detected. Only a broad aromatic/alkene NMR 
signal could be detected for CCHG, CCHG+, and CCIG.  This signal was shifted upfield 
relative to that in the precursor HGO, HGO+, and IGO; the peak maximum after 
reduction was at about 118 ppm, very similar to that noted previously36 on other samples 
of reduced GO.   Reduction also had an effect similar to that previously noted36 on the 
drive pressure required to spin the rotor and on the tuning and matching of the 13C and 1H 
channels of the probe. After reduction and annealing in Ar/H2 at 900 °C, no NMR signal 
could be detected for any of the samples, consistent with their becoming even more 
graphite-like.36   
XPS analysis of the black solids showed similar levels of reduction for all three 
materials when they were hydrazine reduced and when they were annealed (Figure 5.10; 
in Figures 5.10B and 5.10C the annealed materials are designated by the prefix “ann” to 
differentiate them from the materials that were only hydrazine reduced). Atomic 
compositions for CCHG+ were C(1s) 89%, N(1s) 3%, and O(1s) 8%; for CCHG: C(1s) 
88%, N(1s) 3%, and O(1s) 9%;  and for CCIG  C(1s) 86%, N(1s) 5%, O(1s) 9%, and 
P(2p) <0.1% (the amount is lower than the detection level of the instrument). 
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Figure 5.10.  The C1s XPS spectra of (A) hydrazine reduced (B) further 300 °C/H2-
annealed materials (C) 900 °C/H2-annealed materials.  The annealed materials in panels 
B and C are designated by the prefix “ann” to differentiate them from the materials in A 
that were only hydrazine reduced.  
 
In order to estimate the degree of graphitization with greater precision for each 
material after being reduced, electrical conductivities were measured. Figure 5.11 
displays scanning electron microscopy (SEM) images of typical CCIG flakes, which were 
deposited on a Si/SiO2 substrate and then reduced by hydrazine vapor.  For the hydrazine 
vapor reduction, Si/SiO2 substrates coated with GO were deposited inside a beaker with 
0.5 mL of hydrazine hydrate and covered with foil. The system was heated using a water 
bath at 95 ºC for 45 min. The material was well-exfoliated; the majority of the flakes on 
the chip were only a few layers thick and several tens of microns in diameter. As an 
example, Figure 5.11A shows an individual flake, which is 60 µm in diameter and, based 
on AFM data, is only 2 nm thick. Typically, the thicknesses of monolayer GO flakes are 
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in the range of 0.7 – 1 nm,11,41-44 so the shown flake most likely consists of 2 layers. The 
largest flake in Figure 5.11B is 160 µm in diameter.  
As-prepared HGO, HGO+ and IGO flakes were deposited on Si/SiO2 substrates 
(heavily doped p-type Si with a 500 nm thermal SiO2 layer), dried in air and then reduced 
by hydrazine vapor in the same flask so that they were exposed to identical reaction 
conditions. Individual flakes of reduced graphene materials with thicknesses ranging 
from 1 - 3 nm were selected for device fabrication. Electronic devices were patterned by 
standard e-beam lithography (we used PMMA as a positive resist), and then 20-nm-thick 
Pt contacts were formed by e-beam evaporation and lift-off process.  Figure 5.11C shows 
a SEM image of a typical electronic device. 
The electrical measurements were performed using a probe station (Desert 
Cryogenics TT-probe 6 system) under vacuum with chamber base pressure below 10-5 
Torr. Normally, the devices were kept under vacuum for at least 2 d before the 
measurements. The current-voltage (IV) data were collected on an Agilent 4155C 
semiconductor parameter analyzer. All CCG flakes in the fabricated electronic devices 
exhibited qualitatively the same electrical properties. They behaved as p-type 
semiconductors in air, but exhibited ambipolar electric field effect in vacuum after 
several days of evacuation in the probe station chamber at ~10-5 Torr (Figure 5.11D).32,45-
47 This effect can be attributed to the desorption of the atmospheric adsorbates that are 
known to cause doping effects in graphene.48 This effect was completely reversible; after 
exposure to air the CCG flakes again behaved as p-type semiconductors. For the 
monolayer (with thickness of about 1 nm) CCHG, CCHG+ and CCIG flakes, we also 
compared electrical properties. CCHG and CCHG+ devices exhibited approximately the 
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same conductivity values ~ 0.05 S/cm, whereas CCIG monolayers were about twice as 
conductive (~ 0.1 S/cm); the above numbers were averaged for 3-5 devices. However, 
considering significant variability in conductivities, found by us for each set of the 
devices and also reported elsewhere,43 it is difficult to conclude whether or not hydrazine-
reduced IGO flakes are indeed more conductive than their HGO and HGO+ counterparts. 
Importantly, these numbers where obtained by 4-probe technique for the flakes that were 
hydrazine-reduced from the original materials under the same conditions. 
Since the hydrazine reduction was not sufficient to achieve high conductivities of 
the flakes, we further reduced the CCG materials by annealing in Ar/H2 at high 
temperatures. Additionally, we fabricated electronic devices based on monolayer CCHG, 
CCHG+ and CCIG flakes annealed in Ar/H2 at 300 or 900 ºC for 0.5 h. For these 
thermally annealed materials, we measured at least 6 devices for each material. We found 
that after the thermal treatment at 300 ºC, the conductivities of the annCCG materials 
dramatically increase up to 2.1 ± 1.4 S/cm (annCCHG), 6.8 ± 4.4 S/cm (annCCHG+) and 
3.5 ± 2.5 S/cm (annCCIG); the scatter plot is shown in Figure 5.11E.  The annCCHG is 
statistically significantly less conductive than the other two samples (p < 0.05, t-test 
assuming equal variance), but due to the small number of devices for annCCHG+ it is 
difficult to determine if the annCCHG+ and annCCIG are significantly different.  The 
statistical significance of the increase in conductivity for annCCHG+ compared to 
annCCIG is marginal (p = 0.04, t-test assuming equal variance) and completely driven by 
the outlier point at 15.0 (removing this point, p = 0.24, t-test assuming equal variance). 
Here, as well as in other cases, the conductivities were calculated assuming the 
thicknesses of the flakes to be 1 nm. CCG materials annealed at even higher temperature 
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 Figure 5.11. Images and conductivities of the CC flakes. (A) and (B) show SEM images 
of CCIG flakes on Si/SiO2 substrate. (C)  SEM image of a typical electronic device for a 
hydrazine-reduced CCIG flake. (D) Source-drain current (Isd) – gate voltage (Vg) 
characteristics of the same electronic device based on a few-layer CCIG flake measured 
in air and in vacuum after 3 d evacuation in the probe station chamber at the pressure of 
~10-5 Torr. (E) Plot of the mean conductivities for the monolayer annCCHG, annCCHG+ 
and annCCIG flakes annealed in Ar/H2 at 300 ºC for 0.5 h. (F) Plot of the mean 
conductivities for the monolayer annCCHG, annCCHG+ and annCCIG flakes annealed 
in Ar/H2 at 900 ºC for 0.5 h. 
 
5.4. Conclusions 
The improved method for producing GO has significant advantages over 
Hummers’ method.  The protocol for running the reaction does not involve a large 
exotherm and produces no toxic gas.  Moreover, the improved method yields a higher 
fraction of well-oxidized hydrophilic carbon material.  This IGO is more oxidized than 
HGO and slightly more oxidized than HGO+.  The IGO possesses a more regular 
structure than the other materials.  An increased number of isolated aromatic rings could 
be a component of this more regular framework structure.  This suggests that the 
improved method might disrupt the basal plane of the graphite less than Hummers’ 
method.  The mechanism for producing IGO with a more regular structure could be based 
on the formation of five-membered cyclic phosphate groups between the phosphoric acid 
and two vicinal diols formed on the graphite basal plane.33 Taken together, this data 
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suggests that the improved method could be advantageous for large-scale production of 
GO. 
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5.7. Experimental Contributions 
I prepared all the graphene oxide compounds. Also, I characterized the material 
by UV/Vis, Raman, AFM, FITR-ATR, TGA, and XPS. Solid 13C NMR was obtained by 
Dr. Alemany, XRD measurements by Wei Lu, TEM images by Dr. Sun, and conductivity 
measurements by Dr. Sinitskii and Alxander Slesarev. Dr. Berlin and Dr. Kosynkin 
assisted with the material preparation and data analysis.    
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Appendix A 
The appendix corresponds to the supporting information of Chapter 1 
 
Characterization of the PEG-HCCs 
 
Figure A1. HCC and PEG-HCC characterization by (A) thermogravimetric analysis, (B) 
X-ray photoelectron spectroscopy, (C) Raman spectroscopy, and (D) dynamic light 
scattering. 
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EPR control samples for O2•- scavenging evaluation       
A                                                                  B 
           
Figure A2. Uncorrected (A) and corrected (B) EPR spectra at pH 7.4 and room 
temperature corresponding to the O2•- and •OH experiments. (A) EPR spectra obtained 
from the O2•- system or DEPMPO-OOH adduct. Spectra were recorded after 70 s of the 
KO2 addition. PEG-HCCs spectrum was corrected by subtracting the signals of the PEG-
HCCs alone (Figure 1.1A).  (B) EPR spectra obtained from the •OH system or DEPMPO-
OH. Spectra were recorded after 90 s of the H2O2 addition. No correction was necessary 
for the •OH scavenging experiments. 
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Figure A3. EPR spectra of a set of control samples corresponding to the O2•- 
experiments. 
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Figure A4. Uncorrected (A) and corrected (B) EPR spectra of the samples treated with 
SOD instead of the PEG-HCCs. The dismutation of the O2•- radicals is being catalyzed by 
SOD causing a signal drop. (A) SOD 0.01 U/mL (B) SOD 0.10 U/mL (C) 1.00 U/mL (D) 
SOD 10.00 U/mL (E) PEG-HCCs (0.07 mg/mL, which is the same concentration used in 
Figure 1.1A). Spectrum E was corrected by subtracting the EPR signal of the PEG-HCCs.  
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Decomposition of the DEPMPO-OH adduct 
If the PEG-HCCs are interacting with the DEPMPO-OH after 90 s, the k of the 
adduct decomposition reaction will change. Therefore, the spin-adduct decay was 
followed for 30 min, using the signal amplitude of the peak localized at 3281.080 G as a 
reference (Figure A5). The adduct decomposition behaves as a 1st order reaction 
(Equation A1). 
െ
݀ሾDEPMPO െ OHሿ
݀ݐ
ൌ ݇ሾDEPMPO െ OHሿ (Equation A1) 
lnሾDEPMPO െ OHሿ ൌ െ݇ݐ ൅ lnሾDEPMPO െ OHሿ௧బ  (Equation A2) 
 
Figure A5. EPR signal decay of the DEPMPO-OH adduct. Each point represents the 
average of the signal intensities at 3281.080 G corresponding to 3 independent 
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experiments for Control and PEG-HCCs treatment, and, 2 independent experiments for 
PEG treatment. Error bars correspond to the standard error (SE). 
Figure A6 displays the integrated 1st order curves. (Equation A2). The k values 
obtained were 0.0006, 0.0005, and 0.0007 s-1 for the control, PEG, and PEG-HCCs 
treatment respectively. These values indicate that neither PEG-HCCs nor PEG promote 
the decomposition of DEPMPO-OH after 90 s.   
 
Figure A6. Linear regression corresponding to the 1st order law (Equation A2). The slope 
of each curve represents –k. 3 independent experiments were run for Control and PEG-
HCCs treatments and, 2 independent experiments for PEG treatment. Error bars 
correspond to the standard error (SE). 
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EPR control samples for •OH scavenging evaluation 
 
Figure A7. EPR spectra of a set of control samples corresponding to the •OH 
experiments.  
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Stability of the EPR signal of the PEG-HCCs in different buffers 
 
Figure A8. EPR spectra of the PEG-HCCs at different pHs. A) pH 4 (citrate buffer). B) 
pH 7.4 (PBS). C) pH 9 (borate buffer). 
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NO• scavenging assay  
 
Figure A9. Difference spectrum of metHb and HbO2 in the absence (blue) and presence 
of the PEG-HCCs (red) after being incubated with NO• for 20 ms. The difference 
between the ΔA401-411nm values of the control and the ΔA401-411nm values of PEG-HCCs 
treated system is lower than the experimental error. Experiment was carried out in 
triplicate. 
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Figure A10. Difference spectrum of metHb and HbO2 in the absence (blue) and presence 
of the PEG-HCCs (red) after being incubated with NO• for 1 s. The difference between 
the ΔA401-411nm values of the control and the ΔA401-411nm values of PEG-HCCs treated 
system is lower than the experimental error. Experiment was carried out in triplicate. 
 
Supplementary tables 
Table A1. Evaluation of the EPR signals of a set of control samples corresponding to the 
O2•- experiments. 
Samples Observations 
PEG-HCCs + Buffer + DMSO (pure) PEG-HCCs signal at ~ 3317 G 
PEG + Buffer + DMSO (pure) -  
DEPMPO + Buffer + DMSO (pure) - 
DEPMPO + Buffer + PEG-HCCs + DMSO 
(pure) 
PEG-HCCs signal at ~ 3317 G  
(higher intensity) 
DEPMPO + Buffer + PEG + DMSO (pure) - 
PEG-HCCs + Buffer + KO2/DMSO PEG-HCCs signal at ~ 3315 G 
PEG + Buffer + KO2/DMSO - 
KO2/DMSO + Buffer  - 
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Table A2. Evaluation of the EPR signals of a set of control samples corresponding to the 
•OH experiments. 
Samples Observations 
Fe+2 in PBS No signal 
DEPMPO + Fe+2 No signal 
DEPMPO + H2O2 No signal 
DEPMPO No signal 
DEPMPO + PEG-HCCs + H2O2 No signal 
DEPMPO + PEG + H2O2 No signal 
DEPMPO + PEG-HCCs + Fe+2 No signal 
DEPMPO + PEG + Fe+2 No signal 
DEPMPO + PEG-HCCs No signal 
DEPMPO + PEG No signal 
PEG-HCCs + H2O2 
Depreciable 
(3312-3320 G) 
PEG + H2O2 No signal 
PEG-HCCs + Fe+2 No signal 
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PEG + Fe+2 No signal 
PEG-HCCs + Fe+2 + H2O2 (nanoparticle + Fenton rxn) No signal 
PEG + Fe+2 + H2O2 (polymer + Fenton rxn) No signal 
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Appendix B 
The entirely appendix was copied from the supporting information of 
reference #1 of this section (Chapter 2) 
Protection of b.End3 Cells from Oxidative Stress-Induced Death - 
Intracellular Superoxide Cell Culture Model 
bEnd.3 cells (~200,000/well, passaged less than 10 times) were plated in 6-well 
plates. To each well was added 2 ml of ATCC complete growth medium (Dulbecco's 
modified Eagle's medium with 4 mM L-glutamine adjusted to contain 1.5 g/l sodium 
bicarbonate and 4.5 g/l glucose, 90%; fetal bovine serum, 10%).  Cells were incubated at 
37 °C with 5% CO2 for 72 h. Media was removed and replaced with 1 ml fresh media. 
Cells were then treated with 15 μl/well 3mM Antimycin A or 1 × PBS. This dose was 
selected empirically to provide a midrange toxicity of the bEnd.3 cells. Cells were 
incubated at 37 °C with 5% CO2 for 10 min then one of the following was added: 40 
μl/well of 100 mg/l PEG-HCCs, or 40 U/well PEG-SOD. Cells were then incubated at 37 
°C with 5% CO2 for 24 h. Cells were washed twice with 1 × PBS, removed from wells 
with 0.5 ml trypsin, suspended in 2 ml PBS with 2% fetal calf serum, and washed twice. 
Cells were resuspended in 0.5 ml 1 × PBS and counted on a Vi-Cell XR Analyzer 
(Beckman Coulter, Brea, CA). Viable cells/ml was recorded and the percent relative to 
control was calculated from the PBS-treated control cells. 
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Figure B1. Cell survival with antioxidant treatment. Antimycin A was used to induce cell 
death (~30% mortality) in bEnd.3 cells. Cells were then treated with PEG-HCCs or the 
known antioxidant PEG-SOD (SOD). After 24 hours, cell survival was determined with a 
trypan blue assay and the antimycin A-treated cells (striped bars) were compared to cells 
not stressed with Antimycin A (solid bars). * p-value <0.05. 
 
ORAC assay 
The antioxidant capacity of the PEG-HCCs was compared by ORAC to known 
antioxidants vitamin C, caffeic acid, and catechin. The linear relationship between the net 
area and antioxidant concentration was evaluated by using a set of trolox and PEG-HCCs 
standards (Figures B2- B4). Table B1 summarizes the correlation coefficient, slope, and 
intercept of the trolox standard curves obtained in each run. The assay was consistent for 
all concentrations tested. For comparison and TME calculations, the concentrations of 
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vitamin C, caffeic acid, catechin, trolox, and PEG-HCCs were kept constant at 1.6 µg/mL 
(Figure 3A, Table B2). 
 
Table B1. Summary of Trolox Calibration curve for each run related to known 
antioxidants evaluation Y(Net. AUC) =  a + b X(mg/mL). Accepted R2 >0.9900. Slope 
and intercept errors calculated at 95% confidence. 
Run R2 Slope (b) Intercept (a) Observations 
1 0.9982 424.9 ± 18.1 0.677 ± 0.599 3 standards 
2 0.9991 399.9 ± 12.1 -0.325 ± 0.399 3 standards 
3 0.9991 431.0 ± 32.5 3.364 ± 0.439 3 standards 
4 0.9998 387.1 ± 5.4 2.980 ± 0.179 3 standards 
Average 0.9990 410.7 ± 20.7 1.674 ± 1.784  
 
Table B2. TME corresponding to the known antioxidants evaluation. The concentration 
of each compound was the same 1.6µg/mL. Quality control samples were also run for 
each set indicating a (%RSD) of 35% and (%REC) of 95%. 
Run Vitamin C Caffeic Acid Catechin Trolox PEG-HCCs 
1 1.02 7.04 5.68 1.00 2.96 
2 0.78 9.68 7.58 1.00 3.73 
3 0.30 5.38 4.25 1.00 2.07 
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4 0.22 6.43 4.78 1.00 2.24 
Average 0.58 7.13 5.57 1.00 2.75 
SD 0.38 1.83 1.46 n.a 0.76 
SE 0.19 0.92 0.73 n.a 0.38 
 
 
Figure B2.  Fluorescence decay and calibration curves. (A) Trolox concentration effect 
on fluorescence decay curve induced by AAPH.  (B) PEG-HCCs concentration effect on 
fluorescence decay curve after AAPH addition. (C) Liner regression of Net AUC of 
trolox and PEG-HCC. An approximation of the Trolox mass equivalent can be estimated 
dividing the slope of the sample by the trolox slope (TMEPEG-HCC = 3.12) 
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Figure B3. Typical fluorescence decay and calibration curves obtained from different 
antioxidants. (A) Fluorescence decay curve obtained during the vitamin C, caffeic acid, 
catechin, and PEG-HCC evaluation.  (B) Liner regression of Net AUC of trolox 
corresponding to the decay curve A. (C) Curve C represents the TME values 
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corresponding to the different knownantioxidants and carbon nanoparticles respectively. 
Trolox is the reference compound (TMEtrolox=1). 
 
Figure B4. Typical fluorescence curves obtained when PBS, Trolox, PEG-HCCs, and the 
fluorescent probe were not mixed with AAPH (control 1). Note that fluorescent intensity 
remained stable during the experiment and the intensity is not affected by the 
nanoparticles. 
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Appendix C 
The entirely appendix was copied from the supporting information of 
reference #1 of this section (Chapter 3) 
Supplementary figures 
 
Figure C1. Characterization of the PEG-HCCs. (A) UV- spectrum of the PEG-HCCs in 
water. Concentration of the particles is estimated based on the carbon core absorbance at 
763 nm using ε = 0.01040 mL/µg (indicated with a X).This wavelength is not used for 
biological assays. (B) TGA shows a 95% weight loss (50 – 850 ºC at 10 ºC/min rate 
under Ar). The pronounced weight loss around 400 ºC (84%) corresponds to the C-O 
functionalities of the PEG. (C) XPS spectrum of C(1s) reflects the signal corresponding 
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to C=C at 284.5 eV as well as the strong signal corresponding to the C-O 
functionalization  at 286.0 eV related to the PEG chains.  
 
 
Figure C2. Images of mock, PEG and PEG-HCC-treated b.End.3 cells. Cell nuclei were 
stained with DAPI (blue), cell membranes with Wheat Germ Agglutinin 594 (red), and 
PEG and PEG-HCCs were stained using a primary antibody against PEG with an Alexa-
100 µm 100 µm 100 µm
100 µm 100 µm 100 µm
100 µm 100 µm 100 µm
A B C
D E F
G H I
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633 conjugated secondary antibody (orange). Each set of images was taken with the same 
settings on a Zeiss LSM 510 confocal microscope, and are shown at the same 
brightness/contrast levels. (A) The membrane and nuclei stained cells, (B) PEG-stained, 
and (C) the overlapped images of the mock treated cells. (D) The membrane and nuclei 
stained cells, (E) PEG-stained, and (F) overlapped images of the PEG-treated cells. (G) 
The membrane and nuclei stained cells, (H) PEG-stained, and (I) overlapped images of 
the PEG-HCC-treated cells. When PEG-HCC-treated cells were stained with the 
secondary antibody only, no signal was observed indicating that there is no non-specific 
antibody staining.  
 
A B C
D E F
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Figure C3. High resolution images of PEG-HCC-treated and PEG b.End.3 cells. Cell 
nuclei were stained with DAPI (blue), cell membranes with Wheat Germ Agglutinin 594 
(red), and PEG and PEG-HCCs were stained using a primary antibody against PEG with 
an Alexa-633 conjugated secondary antibody (orange). Each set of images were taken 
with the same settings on a Zeiss LSM 510 confocal microscope, and are shown at the 
same brightness/contrast levels. (A) The membrane and nuclei-stained cells, (B) PEG-
stained, and (C) overlapped images of the PEG-HCC-treated cells. (D) The membrane 
and nuclei stained cells, (E) PEG-stained, and (F) overlapped images of the PEG-treated 
cells.  
 
 
Figure C4. Fine optical sectioning and orthogonal rendering of z-stacks is required in 
order to resolve the cytoplasm from the cell membrane, which is stained with Wheat 
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Germ Agglutinin (WGA) 594 (red). Shown in (A) is a section through a cell stained with 
WGA (red), DAPI (blue), and an antibody against PEG to visualize the internalized PEG-
HCCs (green). Panels (B) through (E) show an orthogonal slice through the same cell 
shown in (A), with the following stains: (B) WGA (red), DAPI (blue), and PEG (green); 
(C) WGA (red); (D) WGA (red) and PEG (green); (E) WGA (red) and DAPI (blue). 
Visualizing the cell in this way verifies that the WGA staining is specific to the 
membrane, and that the PEG-HCCs are located intracellularly. 
 
A.        B. 
 
 
 
Figure C5. DAF-2DA intensity in bEnd.3 cells that spontaneously generate NO after 
treatment with increasing concentrations of PEG-HCCs. DAF-2DA is a NO sensitive 
dye. (A) Concentrations of PEG-HCCs up to 30 mg/L did not quench NO dye 
fluorescence (p>.05 for all comparisons). (B) Fluorescent microscope image of bEnd.3 
cells with DAF-2DA. Error bars are s.e.m. Scale bar is 50 μm .  Statistics are described in 
Supplementary Methods section.  
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Figure C6. Controls for intracellular SO assay to determine whether there is direct 
interference between the PEG-HCCs and the fluorescent assay. Cells were treated with or 
without antimycin A (a mitochondrial toxin that induces SO production). PEG-HCCs 
were added 15 min later (grey bars) followed by DHE (SO-specific dye) where indicated 
by +. There was no reduction in either non-specific fluorescence (first three bars) or 
background fluorescence after addition of DHE (bars 4 and 5). The last combination (bar 
6), DHE and antimycin A-treated cells demonstrated, as expected, a significantly higher 
DHE staining compared to the untreated control (first bar). Statistics are the same as 
Figure 3.2 and error bars are s.e.m. Means are the results of a minimum of 5 separate 
experiments. 
 
 
  179 
 
 
A. 
 
 
B. 
 
 
0
10
20
30
40
TBI 60 min TBI + 40 min TBI + 50 min TBI + 60 min
Le
si
on
 V
ol
um
e 
(m
m
3 )
60 min HSTBI only
TBI + 40 min TBI + 50 TBI + 60 min
  180 
 
 
C. 
 
Figure C7. Histological and behavioral evidence that the combination of TBI and 
hypotension worsens outcome.  (A, B) The large change in lesion volume (noted with 
yellow arrows in A) if TBI is associated with hypotension for 40, 50 and 60 min; 
recorded 14 days post TBI/ hypotension.  (C) The decline of behavioral abilities tracks 
with increased duration of hypotension.  Reproduced from ref 30 of main paper.  
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Figure C8. MAP for rats undergoing sham surgery or TBI and hemorrhagic shock (TBI 
+ HS). Drugs (PEG-HCC or PBS vehicle) were given where indicated. Time 0 min 
indicates when the TBI was performed. Phase 1 = TBI + hypotension; Phase 2 = PBS 
during “prehopital-ambulance phase”; Phase 3 = blood reinfusion during “definitive-
hospital phase”.  No statistical differences (p-value >0.05) seen with data calculated with 
repeated measures; ANOVA with Bonferroni post-test. Error bars are s.e.m. 
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Supplementary tables 
Table C1. TBI impact characteristics and rat weights 
 
Mean ± SD 
 
Vehicle PEG-HCCs p -value 
Rat weight (grams) 287.1 ± 27.0 279.0 ± 16.0 0.3955 
Impact characteristics    
 Velocity (m/s) 3.29 ± 0.41 3.25 ± 0.49 0.8388 
  Duration (ms) 79.0 ± 8.9 80.8 ± 5.7 0.5733 
Statistics: Repeated measures ANOVA 
 
Table C2. Arterial blood gases in the TBI and hypotension model at baseline, end of 
hypotension and during the hospital phase.  
Arterial blood gases (mean ± SD) Vehicle PEG-HCCs p -value 
Baseline pH 7.44 ± 0.06 7.45 ± 0.07 0.775 
 pCO2 41.46 ± 4.07 39.08 ± 7.4 0.8425 
 pO2 300.9 ± 80.7  309.5 ± 87.6 0.9144 
Hypotension  pH 7.39 ± 0.01 7.30 ± 0.05  
 pCO2 41.85 ± 1.06 47.83 ± 4.99  
 pO2 139.1 ± 48.7  101.2 ± 36.4  
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Hospital  pH 7.29 ± 0.11 7.40 ± 0.09  
 pCO2 41.77 ± 1.99 37.73 ± 9.44  
  pO2 249. 9 ± 100.3 295.9 ± 85.7   
pCO2 is the partial pressure of CO2 
pO2 is the partial pressure of O2 
Statistics: Repeated measures ANOVA 
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Appendix D 
The entirely appendix was copied from the supporting information of 
reference #1 of this section (Chapter 4) 
Supplementary figures 
 
Figure D1. Antigenic mapping of GBM cultures can be used to determine the levels of 
surface antigens allowing IgG selection for optimization of hydrophilic carbon cluster 
antibody enhancement system (HADES) anti-cancer therapy. Three control cultures of 
GFAP IL-13R 
EGFR GFAPAB/SN-38/PEG-HCCs 
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 a  b
 d c
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GBM with Hoechst prior to fixation in paraformaldehyde (PFA). The washed 
cells/blocked cells were initially incubated with monoclonal antibodies to (a) GFAP, (b) 
IL-13R  and (c) EGFR and then with a red fluorescently labeled anti-mouse antibody. 
The ratios of red fluorescence, per cell, are indicated in the red text. The final panel (d) 
shows the binding of GFAPAB/SN-38/PEG-HCCs to these cells. This panel shows that 
anti-GFAP IgG adsorbed to PEG-HCCs are co-localized with the GBM cell surface, after 
1 h incubation, as in (a). We used the same conditions as used in Figure 4.2, with 5 µM 
SN-38 as GFAPAB/SN-38/PEG-HCCs, with cells fixed after 1 h incubation and then 
labeled with a secondary. All figures are at 20× magnification. All figures are at 20× 
magnification. 
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Figure D2. The effects of 24 h treatments of HADES and trident therapy treatments in 
HCN, measured using the bicinchoninic acid (BCA) protein method. On the left are four 
HCN controls: 100 µM carbonyl cyanide m-chlorophenyl hydrazone (CCCP) (100% cell 
death), saline vehicle, PEG-HCCs and IgG/PEG-HCCs using monoclonal antibodies 
toward GFAP, IL-13R or EGFR.. Three HADES treatments are then shown where PEG-
HCCs loaded with the drugs Vin, Doc, or SN-38 were added to HCN without antibodies 
(black) or with antibodies (gray). The final pairing shows that trident therapy without 
antibodies (black) is no more toxic than when Drug/PEG-HCCs is presented to cells with 
all three antibodies. Protein levels were measured in 7 wells ± SD, only in the CCCP 
positive control and the untargeted/targeted trident therapy were the HCN protein levels 
less than the control levels; p<0.05, ANOVA and Tukey post-hoc test. 
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Figure D3. PEG-HCCs are not toxic towards confluent cultures of human cortical 
neurons (HCN), normal human astrocytes (NHA), and glioblastoma multiforme (GBM) 
following 24 h exposure to high very concentrations of PEG-HCCs as shown by cell 
protein levels (n = 8 wells; error bars SD). 
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 BT-115 GBM 500 nM Treated magnification x20  
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C 
 
 
 BT-128 GBM 500 nM Treated magnification x20  
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E 
 
 
 
 Normal Human Astrocytes 500 nM Treated magnification x20  
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F 
 
 
Figure D4. The pattern of cell death in (A-C) three GBMs, (D) one anaplastic 
astrocytoma, (E) NHA and (F) HCN cell cultures treated as in Figure 4.3. The upper three 
rows of A-F are all at 20× magnification. However, the bottom row of A-F is expanded 
further by 4× using a non-linear scale (G = 0.5), showing DNA staining by Hoechst at 
higher magnification, which allows easier identification of the known outcomes of the 
microtubule disrupting drugs; Docetaxel (Doc) and Vinblastine (Vin). Mitotic catastrophe 
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is found using both drugs, with many nuclei having atypical morphology.2,3 The 
distorted/cog wheel shaped nuclei, indicative of cell cycle arrest at the G2/M phase, are 
clearly visible in the Doc treated cancer cells.4 
 
References 
1. Sharpe, M. A.; Marcano, D. C.; Berlin, J. M.;  Widmayer, M. A.; Baskin, D. S.; 
Tour, J. M. Antibody-targeted nanovectors for the treatment of brain cancers. ACS 
Nano, 2012, 6, 3114-3120. 
2.  Maurya, D.; Ayuzawa, R.; Doi, C.; Troyer, D.; Tamura, M. Topoisomerase I 
Inhibitor SN-38 effectively attenuates growth of human non-small cell lung cancer 
cell lines in vitro and in vivo. J. Environ. Pathol. Toxicol. Oncol., 2011, 30, 1-10. 
3. Upreti, M.; Lyle, C. S.; Skaug, B.; Du, L.; Chambers, T. C. Vinblastine-induced 
apoptosis is mediated by discrete alterations in subcellular location, oligomeric 
structure, and activation status of specific Bcl-2 family members. J. Biol. Chem., 
2006, 281, 15941-15950. 
4. Hoshino, T.; Wilson, C. B.; Muraoka, I. The Stathmo kinetic (mitostatic) effect of 
vincristine and vinblastine on human gliomas. Acta Neuropathologica, 1979, 47, 
21-25. 
